



Peer-Reviewed Publications
Co-Authored by STATinMED Research
2016-2021



STATinMED

The Authority in Real-World Evidence

Peer-reviewed Publications

1. Levy M, Xie L, Wang Y, Neumann F, Srivasta S, Naranjo D, Xu J, Zhang Q, Dalal M. Comparison of incidence/occurrence of cardiovascular events between ponatinib vs bosutinib among patients with at least one prior line of tyrosine kinase inhibitors in chronic myeloid leukemia in a community setting in the United States. *Cancer Treat Res Commun*. Forthcoming 2021.
2. Lip GYH, Keshishian AV, Zhang Y, Kang A, Dhamane AD, Luo X, Klem C, Ferri M, Jiang J, Yuce H, Deitelzweig S. Oral anticoagulants for non-valvular atrial fibrillation in patients with high risk of gastrointestinal bleeding. *JAMA Network Open*. Forthcoming 2021.
3. Hood RC, Borra S, Fan L, Pollom RD, Huang A, Chen J. Treatment patterns and outcomes, before and after Humulin R U-500 initiation, among high-dose type 2 diabetes mellitus patients in the United States. *Endocrine Practice*. Forthcoming 2021.
4. Chen G, Lisssoos T, Dieyi C, Null KD. Development and validation of an inflammatory bowel disease (IBD) severity index using US administrative claims data: A retrospective cohort study. *Inflamm Bowel Dis*. Forthcoming 2021.
5. Rubin DT, Griffith J, Zhang Q, Hepp Z, Keshishian A. The impact of intestinal complications on health care costs among inflammatory bowel disease patients treated with anti-tumor necrosis factor therapies. *Inflamm Bowel Dis*. Forthcoming 2021.
6. Hutson T, Liu F, Dieyi C, Kim R, Krulewicz S, Kasturi V, Bhanegaonkar A. Effects of early vs delayed progression on clinical and economic outcomes in patients with metastatic renal cell carcinoma treated with tyrosine kinase inhibitors in the first-line setting: Results from the IMPACT RCC Real-World Study. *J Managed Care Specialty Pharm*. Forthcoming 2021.
7. Cohen AT, Keshishian A, Lee T, Rosenblatt L, Hlavacek P, Sah J, Luo X. Effectiveness and safety of apixaban, LMWH, and warfarin among high-risk subgroups of VTE patients with active cancer. *Curr Med Res Opin*. Forthcoming 2021.
8. Deitelzweig S, Keshishian A, Kang A, Dhamane AD, Luo X, Klem C, Rosenblatt L, Mardekian J, Jiang J, Yuce H, Lip GYH. Use of non-vitamin K antagonist oral anticoagulants among patients with nonvalvular atrial fibrillation and multimorbidity. *Adv Ther*. 2021;38(6):3166-84.
9. Bhanegaonkar A, Pandya S, Zheng Y, Kim R, Krulewicz S, Kasturi V, Phatak H. Real-world outcomes among US Veterans Health Administration patients newly-diagnosed with metastatic renal cell carcinoma and treated with first-line monotherapy. *Adv Ther*. 2021;38(5):2644-61.
10. Huang H, Schmerold L, Dembek C, Fan Q, Dieyi C, Williams GR, Loebel A. Healthcare resource utilization, costs and treatment patterns in patients with bipolar disorder treated with lurasidone or cariprazine. *J Med Econ*. 2021;24(1):352-62.
11. Cohen A, Keshishian A, Lee T, Wygant G, Rosenblatt L, Hlavacek P, Mardekian J, Wiederkehr D, Sah J, Luo X. Effectiveness and safety of apixaban, low-molecular-weight heparin, and warfarin among venous thromboembolism patients with active cancer: A U.S. claims data analysis. *Thromb Haemost*. 2021;121(3):383-95.
12. Guo JD, Hlavacek P, Rosenblatt L, Keshishian A, Russ C, Mardekian J, Ferri M, Poretta T, Yuce H, McBane R. Safety and effectiveness of apixaban compared with warfarin among clinically-relevant subgroups of venous thromboembolism patients in the United States Medicare population. *Thromb Res*. 2021;198:163-70.
13. Lip G, Keshishian A, Kang A, Dhamane A, Luo X, Li X, Balachander N, Rosenblatt L, Mardekian J, Pan X, Di Fusco M, Garcia Reeves A, Yuce H, Deitelzweig S. Oral anticoagulants for non-valvular atrial fibrillation in frail elderly patients: Insights from the ARISTOPHANES study. *J Intern Med*. 2021;289:42-52.

14. Bolge SC, Kariburyo F, Yuce H, Fleischhackl R. Predictors and outcomes of hospitalization for influenza: Real world evidence from the United States Medicare population. *Infect Dis Ther*. 2020 [epub ahead of print].
15. Obando C, Ding Z, Muser E, Vaidya N, Qiang W, Sun X, Wang H, Mallampati R, Xie L. Persistence, dose titration, and health care resource utilization among Crohn's disease patients treated with ustekinumab: A real-world analysis in the United States. *Adv Ther*. 2020;37(5):2127-43.
16. Huang Q, Borra S, Li J, Wang L, Shrestha S, Sundaram M, Janjan N. Time to next treatment, healthcare resource utilization, and costs associated with ibrutinib use among US veterans with chronic lymphocytic leukemia/small lymphocytic lymphoma: A real-world retrospective analysis. *J Manag Care Spec Pharm*. 2020;26(10):1266-75.
17. Sobhy MA, Khoury M, Almahmeed WA, Sah J, Di Fusco M, Mardekian J, Kherraf SA, Lopes RD, Hersi A. The atrial Fibrillation real World management registry in the Middle East & Africa—Design and rationale. *J Cardiovasc Med*. 2020;21(9):704-10.
18. Shah N, Bhor M, Xie L, Paulose J, Yuce H. Medical resource use and costs of treating sickle cell-related vaso-occlusive crisis episodes: A retrospective claims study. *JHEOR*. 2020;7(1):52-60.
19. Deitelzweig S, Keshishian A, Kang A, Dhamane A, Luo X, Li X, Balachander N, Rosenblatt L, Mardekian J, Pan X, Di Fusco M, Garcia Reeves A, Yuce H, Lip GYH. Effectiveness and safety of oral anticoagulants among NVAF patients with obesity: Insights from the ARISTOPHANES study. *J Clin Med*. 2020;9(6):1633.
20. Lip GYH, Keshishian AV, Kang AL, Li X, Dhamane A, Luo X, Balachander N, Rosenblatt L, Mardekian J, Nadkarni A, Pan X, Di Fusco M, Garcia Reeves AB, Yuce H, Deitelzweig SB. Effectiveness and safety of oral anticoagulants among non-valvular atrial fibrillation patients with diabetes mellitus. *Mayo Clin Proc*. 2020;95(5):929-43.
21. Amin A, Keshishian A, Trocio J, Dina O, Le H, Rosenblatt L, Liu X, Mardekian J, Zhang Q, Baser O, Nadkarni A, Vo L. A real-world observational study of hospitalization and health care costs among non-valvular atrial fibrillation patients prescribed oral anticoagulants in the U.S. Medicare population. *J Manag Care Spec Pharm*. 2020;26(5):639-51.
22. Ramaswamy K, Lechpammer S, Mardekian J, Huang A, Schultz NM, Sandin R, Wang L, Baser O, George DJ. Economic outcomes in patients with chemotherapy-naïve metastatic castration-resistant prostate cancer treated with enzalutamide or abiraterone acetate plus prednisone. *Adv Ther*. 2020;37(5):2083-97.
23. Patel C, El Khoury A, Huang A, Wang L, Bashyal R. Healthcare resource utilization and costs among patients with schizophrenia switching from oral risperidone/paliperidone to once-monthly paliperidone palmitate: A veterans health administration claims analysis. *Curr Ther Res*. 2020;92:100587.
24. Gandhi K, Wei W, Huang A, Wang L, Iyer R, Katz NP. A real-world study using claims data to evaluate possible failure of opioid treatment regimens among patients with hip and/or knee osteoarthritis in the US. *Clinicoecon Outcomes Res*. 2020;12:285-97.
25. Cohen J, Beaubrun A, Bashyal R, Huang A, Li J, Baser O. Real-world adherence and persistence for newly-prescribed HIV treatment: Single versus multiple tablet regimen comparison among US Medicaid beneficiaries. *AIDS Res Ther*. 2020;17(1):12.
26. Sbarigia U, Kariburyo F, Sah J, Colasurdo J, Xie L, Katz EG, Sylvester S. Evaluating the effect of standard of care treatment on burden of chronic hepatitis B: A retrospective analysis of the United States veterans population. *Adv Ther*. 2020;37(3):1156-72.
27. Parasuraman S, Yu J, Paranagama D, Shrestha S, Wang L, Baser O, Scherber R. Elevated white blood cell levels and thrombotic events in patients with polycythemia vera: A real-world analysis of Veterans Health Administration data. *Clin Lymphoma Myeloma Leuk*. 2020;20(2):63-9.

28. Kariburyo F, Xie L, Sah J, Li N, Lofland JH. Real world medication use and economic outcomes in incident systemic lupus erythematosus patients in the United States. *J Med Econ.* 2020;23(1):1-9.
29. Chowdhury R, Franchino-Elder J, Wang L, Yuce H, Wang C, Hartaigh BO. Healthcare resource utilization and expenditures among newly diagnosed elderly non-valvular atrial fibrillation patients initiating oral anticoagulants. *J Med Econ.* 2019;22(12):1338-50.
30. El Khoury A, Patel C, Huang A, Wang L, Bashyal R. Transitioning from oral risperidone or paliperidone to once-monthly paliperidone palmitate: a real-world analysis among Veterans Health Administration patients with schizophrenia who have had at least one prior hospitalization. *Curr Med Res Opin.* 2019;35(12):2159-68.
31. Keshishian A, Xie L, Dembek C, Yuce H. Reduction in hospital readmission rates among Medicare beneficiaries with chronic obstructive pulmonary disease: A real-world outcomes study of nebulized bronchodilators. *Clin Ther.* 2019;41(11):2283-96.
32. Shah N, Bhor M, Xie L, Halloway R, Arcona S, Paulose J, Yuce H. Treatment patterns and economic burden of sickle-cell disease patients prescribed hydroxyurea: A retrospective claims-based study. *Health Qual Life Outcomes.* 2019;17(1):155.
33. Peacock WF, Coleman CI, Wells P, Fermann GJ, Wang L, Baser O, Schein J, Crivera C. Clinical and economic outcomes in low-risk pulmonary embolism patients treated with rivaroxaban versus standard of care. *JHEOR.* 2019;6(3):160-73.
34. Patel C, El Khoury A, Huang A, Wang L, Baser O, Joshi K. Health outcomes among patients diagnosed with schizophrenia in the US Veterans Health Administration population who transitioned from once-monthly to once-every-3-month paliperidone palmitate: An observational retrospective analysis. *Adv Ther.* 2019;36(10):2941-53.
35. Parasuraman S, Yu J, Paranagama D, Shrestha S, Wang L, Baser O, Scherber R. Hematocrit levels and thrombotic events in patients with polycythemia vera: An analysis of veterans health administration data. *Ann Hematol.* 2019;98:2533-9.
36. Nazareth T, Kariburyo F, Kirkemo A, Xie L, Pavlova-Wolf A, Bartels-Peculis L, Vaidya N, Sim JJ. Patients with idiopathic membranous nephropathy: A real-world clinical and economic analysis of U.S. claims data. *J Manag Care Spec Pharm.* 2019;25(9):1011-20.
37. Amin A, Keshishian A, Dina O, Dhamane A, Nadkarni A, Carda E, Russ C, Rosenblatt L, Mardekian J, Yuce H, Baker CL. Comparative clinical outcomes between direct oral anticoagulants and warfarin among elderly patients with non-valvular atrial fibrillation in the CMS Medicare population. *J Thromb Thrombolysis.* 2019;48(2):240-9.
38. Deitelzweig S, Keshishian A, Li X, Kang A, Dhamane AD, Luo X, Balachander N, Rosenblatt L, Mardekian J, Pan X, Nadkarni A, Di Fusco M, Garcia Reeves AB, Yuce H, Lip GYH. Comparisons between oral anticoagulants among older nonvalvular atrial fibrillation patients. *J Am Geriatr Soc.* 2019;67(8):1662-71.
39. Shah N, Bhor M, Xie L, Paulose J, Yuce H. Sickle cell disease complications: Prevalence and resource utilization. *PLoS One.* 2019;14(7):e0214355.
40. Ng-Mak D, Messali A, Huang A, Wang L, Loebel A. Hospitalization risk in patients with schizophrenia treated with dose-equivalent antipsychotics. *Am J Manag Care.* 2019;25(14 Suppl):S279-S286.
41. Wells P, Peacock WF, Fermann GJ, Coleman CI, Wang L, Baser O, Schein J, Crivera C. The value of sPESI for risk stratification in patients with pulmonary embolism. *J Thromb Thrombolysis.* 2019;48(1):149-57.
42. Zhou FL, Nicholls C, Xie L, Wang Y, Vaidya N, Meneghini LF. Hypoglycaemia and treatment patterns among insulin-treated patients with type 2 diabetes who switched to insulin glargine 300 units/mL versus other basal insulin in a real-world setting. *Endocrinol Diabetes Metab.* 2019;2(3):e00073.

43. Gupta K, Trocio J, Keshishian A, Zhang Q, Dina O, Mardekian J, Nadkarni A, Shank TC. Effectiveness and safety of direct oral anticoagulants compared to warfarin in treatment naïve non-valvular atrial fibrillation patients in the US Department of Defense population. *BMC Cardiovasc Disord.* 2019;19(1):142.
44. Shah N, Bhor M, Xie L, Halloway R, Arcona S, Paulose J, Yuce H. Evaluation of vaso-occlusive crises in United States sickle cell disease patients: A retrospective claims-based study. *JHEOR.* 2019;6(3):106-117.
45. Pandya S, Baser O, Wan G, Lovelace B, Potenziano J, Pham AT, Huang X, Wang L. The burden of hypoxic respiratory failure in preterm and term/near-term infants in the United States 2011-2015. *JHEOR.* 2019;6(3):130-41.
46. Wang L, Baser O, Wells P, Peacock WF, Coleman CI, Fermann GJ, Schein J, Crivera C. Predictors of hospital length of stay among patients with low-risk pulmonary embolism. *JHEOR.* 2019;6(2):84-94.
47. Amin A, Garcia Reeves AB, Li X, Dhamane A, Luo X, Di Fusco M, Nadkarni A, Friend K, Rosenblatt L, Mardekian J, Pan X, Yuce H, Keshishian A. Effectiveness and safety of oral anticoagulants in older adults with non-valvular atrial fibrillation and heart failure. *PLOS One.* 2019;14(3):e0213614.
48. Lim J, Samuelsen C, Golembesky A, Shrestha S, Wang L, Griebbsch I. Duration of treatment for patients prescribed first-line afatinib/erlotinib for EGFR mutation-positive NSCLC in the US. *Future Oncol.* 2019;15(13):1493-504.
49. McNamara MA, George DJ, Ramaswamy K, Lechpammer S, Mardekian J, Schultz NM, Wang L, Baser O, Huang A, Freedland SJ. Overall survival by race in chemotherapy-naïve metastatic castration-resistant prostate cancer (mCRPC) patients treated with abiraterone acetate or enzalutamide. *J Clin Oncol.* 2019;37(7):212.
50. Zhao Q, Wang L, Kurlansky PA, Schein J, Baser O, Berger JS. Cardiovascular outcomes among elderly patients with heart failure and coronary artery disease and without atrial fibrillation: A retrospective cohort study. *BMC Cardiovasc Disord.* 2019;19(1):19.
51. Al-Mazrou AM, Baser O, Kiran RP. Alvimopan, regardless of ileus risk, significantly impacts ileus, length of stay, and readmission after intestinal surgery. *J Gastrointestinal Surg.* 2018;22(12):2104-16.
52. Sietsema D, Araujo A, Wang L, Boytsov N, Pandya S, Haynes V, Faries D, Taylor K, Baser O, Jones C. The effectiveness of a private orthopedic practice-based osteoporosis management program to reduce the risk of subsequent fractures. *J Bone Joint Surgery.* 2018;100(21):1819-28.
53. Shah A, Xie L, Kariburyo F, Zhang Q, Gore M. Treatment patterns, healthcare resource utilization and costs among schizophrenia patients treated with long-acting injectable versus oral antipsychotics. *Adv Ther.* 2018;35(11):1994-2014.
54. Gupta K, Trocio J, Keshishian A, Zhang Q, Dina O, Mardekian J, Rosenblatt L, Liu X, Hede S, Nadkarni A, Shank T. Real-world comparative effectiveness, safety, and health care costs of oral anticoagulants in non-valvular atrial fibrillation patients in the United States Department of Defense population. *J Manag Care Spec Pharm.* 2018;24(11):1116-1127.
55. Yazici Y, Xie L, Ogbomo A, Ellis L, Goyal K, Teeple A, Simsek I. Analysis of real-world treatment patterns in a matched rheumatology population that continued innovator infliximab therapy or switched to biosimilar infliximab. *Biologics: Targets Ther.* 2018;8:127-134.
56. Yazici Y, Xie L, Ogbomo A, Ellis L, Goyal K, Teeple A, Mutlu E, Simsek I. A descriptive analysis of real-world treatment patterns of innovator (Remicade®) and biosimilar infliximab in an infliximab-naïve Turkish population. *Biologics: Targets Ther.* 2018;12:97-106.

57. Huang A, Amos TB, Joshi K, Wang L, Nash A. Understanding healthcare burden and treatment patterns among young adults with schizophrenia. *J Med Econ*. 2018;21(10):1026-35.
58. Keshishian A, Greenberg SA, Agashivala N, Baser O, Johnson K. Health care costs and comorbidities for patients with inclusion body myositis. *Curr Med Res Opin*. 2018;34(9):1679-85.
59. Lopes RD, Steffel J, Di Fusco M, Keshishian A, Luo X, Li X, Masseria C, Hamilton H, Friend K, Gupta K, Mardekian J, Pan X, Baser O, Jones WS. Effectiveness/safety of oral anticoagulants in older adults with non-valvular atrial fibrillation and concomitant coronary/peripheral artery disease. *Am J Med*. 2018;131(9):1075-1085.e4.
60. Shrestha S, Baser O, Kwong WJ. Effect of renal function on dosing of non-vitamin K-antagonist direct oral anticoagulants among patients with non-valvular atrial fibrillation. *Ann Pharmacother*. 2018;52(2):147-153.
61. Al-Mazrou AM, Baser O, Kiran RP. The effect of hospital familiarity with complex procedures on overall healthcare burden. *Am J Surg*. 2018;216(2):204-212.
62. Lee S, Xie L, Wang Y, Vaidya N, Baser O. Evaluating the impact of treatment persistence on the economic burden of moderate-to-severe psoriasis and/or psoriatic arthritis patients in the US Department of Defense population. *J Manag Care Spec Pharm*. 2018;24(7):654-63.
63. Huntington S, Keshishian A, McGuire M, Xie L, Baser O. Costs of relapsed diffuse large B-cell lymphoma among Medicare patients. *Leuk Lymphoma*. 2018;59(12):2880-7.
64. Kariburyo F, Wang Y, Cheng IE, Wang L, Morgenstern D, Xie L, Meadows E, Danella J, Cher ML. Observation versus treatment among men with favorable risk prostate cancer in a community-based integrated health care system: a retrospective cohort study. *BMC Urol*. 2018;18(1):55.
65. Sonpavde G, Huang A, Wang L, Baser O, Miao R. Taxane chemotherapy versus anti-androgen agents as first-line therapy for metastatic castration-resistant prostate cancer. *BJU Int*. 2018;121(6):871-9.
66. Lee S, Xie L, Wang Y, Vaidya N, Baser O. Comorbidity and economic burden among moderate-to-severe psoriasis and/or psoriatic arthritis patients in the US Department of Defense population. *J Med Econ*. 2018;21(6):564-70.
67. Lopes RD, Steffel J, Di Fusco M, Keshishian A, Luo X, Li X, Masseria C, Hamilton H, Friend K, Gupta K, Mardekian J, Pan X, Baser O, Jones WS. Effectiveness and safety of oral anticoagulants in adults with non-valvular atrial fibrillation and concomitant coronary/peripheral artery disease. *Am J Med*. 2018;131(9):1075-85.e4.
68. Parasuraman S, Yu J, Paranagama D, Shrestha S, Wang L, Baser O, Scherber R. Cytoreductive treatment patterns among US veterans with polycythemia vera. *BMC Cancer*. 2018;(18):528.
69. Tang WY, Grothe D, Keshishian A, Morgenstern D, Haider S. Pharmacoeconomic and associated cost savings among women who were prescribed systemic conjugated estrogens therapy compared to those without menopausal therapy. *Menopause*. 2018;25(5):493-9.
70. Steward R, Carney P, Law A, Xie L, Wang Y, Yuce H. Long-term outcomes after elective sterilization procedures—a comparative retrospective cohort study of Medicaid patients. *Contraception*. 2018;97(5):428-33.
71. Zhou FL, Xie L, Pan C, Wang Y, Vaidya N, Ye F, Preblich R, Meneghini L. Relationship between treatment persistence and A1C trends among patients with type 2 diabetes newly initiating basal insulin. *Diabetes Obes Metab*. 2018;20(5):1298-301.

72. Khandker RK, Black CM, Xie L, Kariburyo MF, Ambegaonkar BM, Baser O, Yuce H, Fillit H. Analysis of episodes of care in Medicare beneficiaries diagnosed with Alzheimer's disease. *J Am Geriatr Soc*. 2018;66(5):864-70.
73. Lip GYH, Keshishian A, Li X, Hamilton M, Masseria C, Gupta K, Luo X, Mardekian J, Friend K, Nadkarni A, Pan X, Baser O, Deitelzweig S. Effectiveness and safety of oral anticoagulants among non-valvular atrial fibrillation patients: The ARISTOPHANES study. *Stroke*. 2018;49(12):2933-2944.
74. Soo-Hoo S, Nemeth S, Baser O, Argenziano M, Kurlansky P. East meets West: the influence of racial, ethnic and cultural risk factors on cardiac surgical risk model performance. *Heart Asia*. 2018;10(1):e010995.
75. Li X, Keshishian A, Hamilton M, Horblyuk R, Gupta K, Luo X, Mardekian J, Friend K, Nadkarni A, Pan X, Lip GYH, Deitelzweig S. Apixaban 5 and 2.5 mg twice-daily versus warfarin for stroke prevention in nonvalvular atrial fibrillation patients: comparative effectiveness and safety evaluated using a propensity-score-matched approach. *PLOS One*. 2018;13(1):e0191722.
76. Black CM, Fillit H, Xie L, Hu X, Kariburyo MF, Ambegaonkar BM, Baser O, Yuce H, Khandker RK. Economic burden, mortality and institutionalization in patients newly diagnosed with Alzheimer's disease. *J Alzheimers Dis*. 2018;61(1):185-93.
77. Fu RH, Toyoda Y, Li L, Baser O, Rohde CH, Otterburn DM. Smoking and postoperative complications in plastic and general surgical procedures: A propensity-score matched analysis of 294,903 patients from the NSQIP database from 2005 to 2014. *Plastic Reconstruct Surg*. 2018;141(1):226-236.
78. Nguyen C, Xie L, Alley S, Baser O, Wang Z. Epidemiology and economic burden of serotonin syndrome with concomitant use of serotonergic agents: A retrospective study utilizing two large US claims databases. *Prim Care Companion CNS Disord*. 2017;19(6):17m02200.
79. Brekke L, Buysman E, Grabner M, Ke X, Xie L, Baser O, Wei W. The use of decomposition methods in real-world treatment benefits evaluation for patients with type 2 diabetes initiating different injectable therapies: Findings from the INITIATOR study. *Value Health*. 2017;20:1252-59.
80. Amin A, Keshishian A, Vo L, Zhang Q, Dina O, Patel C, Odell K, Trocio J. Real-world comparison of all-cause hospitalizations, hospitalizations due to stroke and major bleeding, and costs for nonvalvular atrial fibrillation patients prescribed oral anticoagulants in a US health plan. *J Med Econ*. 2018;21(3):244-53.
81. Keshishian A, Boytsov N, Burge R, Krohn K, Lombard L, Zhang X, Xie L, Baser O. Examining the impact of medication adherence on risk of subsequent fracture among women with a fragility fracture in the US Medicare population. *J Manag Care Pharm*. 2017;23(11):1178-90.
82. Al-Mazrou AM, Baser O, Kiran RP. Failure of efforts to contain costs of care after colorectal procedures: Nationwide trends in length of stay, costs and post-acute care utilization. *Am J Surg*. 2017;214(5):804-10.
83. Wang L, Baser O, Wells P, Peacock WF, Coleman CI, Fermann GJ, Schein J, Crivera C. Benefit of early discharge among patients with low-risk pulmonary embolism. *PLoS One*. 2017;12(10):e0185022.
84. Dalal MR, Kazemi M, Ye F, Xie L. Hypoglycemia after initiation of basal insulin in patients with type 2 diabetes in the United States: Implications for treatment discontinuation and healthcare costs and utilization. *Adv Ther*. 2017;34(9):2083-92.

85. Amin A, Keshishian A, Trocio J, Dina O, Le H, Rosenblatt L, Liu X, Mardekian J, Zhang Q, Baser O, Vo L. Risk of stroke/systemic embolism, major bleeding and associated costs in non-valvular atrial fibrillation patients who initiated apixaban, dabigatran, or rivaroxaban compared with warfarin in the United States Medicare population. *Curr Med Res Opin.* 2017;33(9):1595-1604.
86. Shrestha S, Miao R, Wang L, Chao J, Yuce H, Wei W. Burden of atopic dermatitis in the United States: analysis of healthcare claims data in the Commercial, Medicare, and Medi-Cal Databases. *Adv Ther.* 2017;34:1989-2006.
87. Kohn CG, Weeda ER, Kumar N, Wells PS, Peacock WF, Fermann GJ, Wang L, Baser O, Schein JR, Crivera C, Coleman CI. External validation of a claims-based and clinical approach for predicting post-pulmonary embolism outcomes among United States veterans. *Intern Emerg Med.* 2017;12(5):613-619.
88. Wei W, Knapp K, Wang L, Chen CI, Craig GL, Ferguson K, Schwartzman S. Treatment persistence and clinical outcomes of tumor necrosis factor inhibitor cycling or switching to a new mechanism of action therapy: Real-world observational study of rheumatoid arthritis patients in the United States with prior tumor necrosis factor inhibitor therapy. *Adv Ther.* 2017;34(8):1936-52.
89. Keshishian A, Boytsov N, Burge R, Krohn K, Lombard L, Zhang X, Xie L, Baser O. Examining the treatment gap and risk of subsequent fractures among females with a fragility fracture in the US Medicare population. *Osteoporos Int.* 2017;28(8):2485-94.
90. Wang L, Baser O, Wells P, Peacock WF, Coleman CI, Fermann GJ, Schein J, Crivera C. Overall effectiveness of rivaroxaban among pulmonary embolism patients. *Clin Ther.* 2017;39(7):1426-36.e2.
91. Kariburyo F, Wang Y, Cheng IN, Wang L, Morgenstern D, Asner I, Xie L, Meadows E, Danella J. Healthcare costs among men with favorable risk prostate cancer managed with observation strategies versus immediate treatment in an integrated health care system. *J Med Econ.* 2017;20(8):825-31.
92. Kariburyo F, Xie L, Teeple A, Tan H, Ingham M. Predicting pre-emptive discussions of biologic treatment: Results from an openness and preference survey of inflammatory bowel disease patients and their prescribers. *Adv Ther.* 2017;34(6):1398-1410.
93. Knight T, Bond C, Popelar B, Wang L, Niewoehner J, Anastassopoulos K, Philbin M. Medical resource utilization in dermatomyositis/polymyositis patients treated with repository corticotropin injection, intravenous immunoglobulin, and/or rituximab. *Clinicoecon Outcomes Res.* 2017;9:271-279.
94. Bent-Enakhil N, Coste F, Xie L, Sanon Aigbogun M, Wang Y, Kariburyo F, Hartry A, Baser O, Neumann P, Fillit H. A real-world analysis of treatment patterns for cholinesterase inhibitors and memantine among newly-diagnosed Alzheimer's disease patients. *Neurol Ther.* 2017;6(1):131-144.
95. Pesa JA, Doshi D, Wang L, Yuce H, Baser O. Health care resource utilization and costs of California-Medicaid patients with schizophrenia treated with paliperidone palmitate once monthly or atypical oral antipsychotic treatment. *Curr Med Res Opin.* 2017;33(4):723-31.
96. Li X, Deitelzweig S, Keshishian A, Hamilton M, Horblyuk R, Gupta K, Luo X, Mardekian J, Friend K, Nadkarni A, Pan X, Lip GYH. Effectiveness and safety of apixaban versus warfarin in non-valvular atrial fibrillation patients in "real-world" clinical practice: A propensity-matched analysis of 76,940 patients. *Thromb Haemost.* 2017;117(6):1072-82.
97. Wei W, Buysman E, Grabner M, Xie L, Brekke L, Ke X, Chu JW, Levin PA. A real-world study of treatment patterns and outcomes in US managed-care patients with type 2 diabetes initiating injectable therapies. *Diabetes Obes Metab.* 2017;19(3):375-86.

98. Nelson WW, Milentijevic D, Wang L, Baser O, Damaraju CV, Schein JR. Patterns of international normalized ratio values among new warfarin patients with non-valvular atrial fibrillation. *Blood Coag Fibrinolysis*. 2016;27(8):899-906.
99. Cai J, Wang Y, Baser O, Xie L, Chow W. Comparative persistence and adherence with newer antihyperglycemic agents to treat patients with type 2 diabetes in the United States. *J Med Econ*. 2016;19(12):1175-86.
100. Xie L, Liu X, Phatak H, Mardekian J, Tan W, Baser O, Ramacciotti E. Warfarin discontinuation in patients with unprovoked venous thromboembolism: A large US insurance database analysis. *Am J Ther*. 2016;23(6):e1744-53.
101. Yu H, Baser O, Wang L. Burden of *Clostridium difficile*-associated disease among patients residing in nursing homes: a population-based cohort study. *BMC Geriatr*. 2016;16:193.
102. Shorr AF, Zilberberg MD, Wang L, Baser O, Yu H. Mortality and costs in *Clostridium difficile* infection disease among the elderly in the United States. *Infect Control Hosp Epidemiol*. 2016;37(11):1331-6.
103. Lip GYH, Keshishian A, Kamble S, Pan X, Mardekian J, Horblyuk R, Hamilton M. Real-world comparison of major bleeding risk among non-valvular atrial fibrillation patients initiated on apixaban, dabigatran, rivaroxaban, or warfarin: A propensity score matched analysis. *Thromb Haemost*. 2016;116(5):975-86.
104. Xie L, Vo L, Keshishian A, Price K, Singh P, Mardekian J, Bruno A, Baser O, Kim J, Tan W, Trocio J. Comparison of hospital length of stay and hospitalization costs among patients with non-valvular atrial fibrillation treated with apixaban or warfarin: an early view. *J Med Econ*. 2016;19(8):769-76.
105. Zilberberg MD, Shorr AF, Wang L, Baser O, Yu H. Development and validation of a risk score for *clostridium difficile* infection in Medicare beneficiaries: A population-based cohort study. *J Am Geriatr Soc*. 2016;64(8):1690-5.
106. Quek RGW, Fox KM, Wang L, Li L, Gandra SR, Wong ND. A US claims-based analysis of real-world lipid-lowering treatment patterns among patients with high cardiovascular disease risk or a previous coronary event. *Am J Cardiol*. 2016;117(4):495-500.
107. Baser O, Wang L, Maguire J. Creating national weights for a patient-level longitudinal database. *JHEOR*. 2016;4(1):80-9.
108. Keshishian A, Wang Y, Xie L, Baser O. The economic impact of symptomatic menopause among low-socioeconomic women in the United States. *Expert Rev Pharmacoecon Outcomes Res*. 2016;16(2):305-13.
109. Fox K, Wang L, Gandra SR, Quek RGW, Li L, Baser O. Clinical and economic burden associated with cardiovascular events among patients with hyperlipidemia: A retrospective cohort study. *BMC Cardiovasc Disord*. 2016;16:13.

Poster Presentations

1. Deitelzweig S, Keshishian A, Kang A, Jenkins A, Atreja N, Schuler P, Jiang J, Lovett K, Yuce H, Lip GYH. Time at home among nonvalvular atrial fibrillation patients treated with non-vitamin K antagonist oral anticoagulants versus warfarin. *ESC 2021*. Online only: August 27-30, 2021.
2. Deitelzweig S, Keshishian A, Kang A, Jenkins A, Atreja N, Schuler P, Jiang J, Lovett K, Yuce H, Lip GYH. Time at home among nonvalvular atrial fibrillation patients treated with non-vitamin K antagonist oral anticoagulants: an ARISTOPHANES analysis. *ESC 2021*. Online only: August 27-30, 2021.

3. Lip GYH, Keshishian A, Kang A, Luo X, Atreja N, Zhang Y, Schuler P, Jiang J, Lovett K, Yuce H, Deitelzweig S. Effectiveness and safety of non-vitamin K antagonist oral anticoagulants versus warfarin among nonvalvular atrial fibrillation patients with prior bleeding events. *ESC 2021*. Online only: August 27-30, 2021.
4. Cohen A, Sah J, Dhamane A, Lee T, Rosenblatt L, Hlavacek P, Emir B, Keshishian A, Yuce H, Luo X. Effectiveness and safety of apixaban vs warfarin among older venous thromboembolism patients stratified by race. *ESC 2021*. Online only: August 27-30, 2021.
5. Cohen A, Sah J, Dhamane A, Lee T, Rosenblatt L, Hlavacek P, Emir B, Keshishian A, Yuce H, Luo X. Effectiveness and safety of apixaban vs warfarin among older venous thromboembolism patients: a subgroup analysis of age. *ESC 2021*. Online only: August 27-30, 2021.
6. Cohen A, Sah J, Dhamane A, Lee T, Rosenblatt L, Hlavacek P, Emir B, Keshishian A, Yuce H, Luo X. Effectiveness and safety of apixaban vs warfarin among venous thromboembolism patients using five US databases: a subgroup analysis of chronic liver disease. *ESC 2021*. Online only: August 27-30, 2021.
7. Cohen A, Sah J, Dhamane A, Lee T, Rosenblatt L, Hlavacek P, Emir B, Keshishian A, Delinger R, Luo X. Effectiveness and safety of apixaban vs warfarin among venous thromboembolism patients using five US databases: A subgroup analysis of thrombophilia. *ISTH 2021 Hematology Conference*. Phil, PA: July 17-21, 2021.
8. Dhamane AD, Keshishian A, Preib MT, Bello T, Russ C, Di Fusco M, Ferri M. Burden and costs of stroke/systemic embolism and major bleeding among elderly non-valvular atrial fibrillation patients prescribed oral anticoagulants. *ISTH 2021 Hematology Conference*. Phil, PA: July 17-21, 2021.
9. Preib MT, Wang Y, Mitrani-Gold FS, Sun X, Joshi AV. Treatment patterns among females with uncomplicated urinary tract infections pre- and post-issue of a Food and Drug Administration warning for fluoroquinolone-associated serious adverse events. *31st European Congress of Clinical Microbiology & Infectious Diseases (ECCMID)*. July 9-12, 2021.
10. Atwater B, Di Fusco M, Keshishian A, Delinger R, Bee G, Ferri M, Jiang J, Seigel L, Yuce H, Guo JD. Geographic variation in anticoagulation among Medicare beneficiaries with non-valvular atrial fibrillation in the United States. *Heart Rhythm Society (HRS) 2021*. June 30: Virtual kick-off, In-person: July 28-31.
11. Munir MB, Hlavacek P, Keshishian A, Guo J, Mallampati R, Ferri M, Russ C, Emir B, Cato M, Yuce H, Hsu JC. Contemporary clinical and economic outcomes among oral anticoagulant treated and untreated elderly patients with atrial fibrillation. *Heart Rhythm Society (HRS) 2021*. June 30: Virtual kick-off, In-person: July 28-31.
12. Russell-Smith TA, Verma S, Liu Y, Sikirica S, Janjan N. Retrospective real-world comparison of clinical and economic burden between first-generation and second-generation tyrosine kinase inhibitors in chronic myeloid leukemia. *European Hematology Association (EHA) Virtual 2021 Congress*. June 9, 2021.
13. Smith TA, Verma S, Liu Y, Sikirica S, Janjan NA. Retrospective real-world comparison of clinical and economic burden between first generation and second-generation tyrosine kinase inhibitors in chronic myeloid leukemia. *2021 American Society of Clinical Oncology (ASCO) Annual Meeting*. June 4-5, 2021.
14. Petri M, Naessens D, Ogbomo A, Lofland JH, Ratiu A, Gutierrez C, Karyekar C. Epidemiology and economic burden associated with mental health comorbidities in systemic lupus erythematosus and lupus nephritis patients. *EULAR 2021 Annual European Congress of Rheumatology*. June 2-5, 2021.

15. Teeple A, Sah J, Mallampati R, Adams C, Waters D, Muser E. Treatment patterns in biologic-experienced Crohn's disease patients using three large commercial claims databases in the United States. *Digestive Disease Week (DDW) 2021*. Virtual: May 21-23, 2021.
16. Sah J, Teeple A, Muser E, Gutierrez C, Adams C, Dassopoulos T. Treatment patterns of biologic agents in ulcerative colitis: A pooled study of three United States claim databases. *Digestive Disease Week (DDW) 2021*. Virtual: May 21-23, 2021.
17. Ogbomo A, Tsang Y, Jaiswal M, Mallampati R, Panjabi S. Examining the direct and indirect healthcare cost among pulmonary arterial hypertension patients. *Virtual ISPOR 2021*: May 17-20, 2021.
18. Siegel CA, Seigel L, Verma S, Sruti I, Mu Q, Gupte-Singh K. Current landscape and treatments used in patients with moderate-to-severe ulcerative colitis. *Virtual ISPOR 2021*: May 17-20, 2021.
19. Maughn K, Chen J, Nelson DR, Fan L, Liu Y, Rey GG. Trajectory of glycated hemoglobin over time among obese type 2 diabetes patients prescribed U-100 basal-only insulin regimens: A US administrative claims data analysis. *Virtual ISPOR 2021*: May 17-20, 2021.
20. Leist T, Le H, Verma S, Cole M, Afolabi M, Tsai W, Keenan A. Real world adherence, persistence, relapse and multiple sclerosis symptoms among patients treated with oral disease-modifying therapies. *Virtual ISPOR 2021*: May 17-20, 2021.
21. Turakhia M, Guo JD, Keshishian A, Delinger R, Sun X, Ferri M, Russ C, Emir B, Cato M, Yuce H, Hlavacek P. Contemporary prevalence estimates of undiagnosed and diagnosed atrial fibrillation in the United States. *American College of Cardiology (ACC) 70th Annual Scientific Session & Expo*. Atlanta, GA: May 15-17, 2021.
22. Dhamane A, Ferri M, Keshishian A, Russ C, Thomas R, Leung G, Emir B, Yuce H, Di Fusco M. Direct oral anticoagulants and warfarin: Effectiveness and safety outcomes among nonvalvular atrial fibrillation patients with multimorbidity. *American College of Cardiology (ACC) 70th Annual Scientific Session & Expo*. Atlanta, GA: May 15-17, 2021.
23. Munir B, Hlavacek P, Keshishian A, Guo JD, Mallampati R, Ferri M, Russ C, Emir B, Cato M, Yuce H, Hsu J. Underutilization of oral anticoagulant therapy among elderly patients with atrial fibrillation: Insights from the United States Medicare database. *American College of Cardiology (ACC) 70th Annual Scientific Session & Expo*. Atlanta, GA: May 15-17, 2021.
24. Deitelzweig S, Sah J, Kang A, Russ C, Preib M, Dhamane A, Ratiu A, Cato M, Alfred T, Levi E, Di Fusco M. Effectiveness and safety of apixaban versus warfarin in obese patients with nonvalvular atrial fibrillation enrolled in Medicare and Veteran Affairs. *American College of Cardiology (ACC) 70th Annual Scientific Session & Expo*. Atlanta, GA: May 15-17, 2021.
25. Dhamane A, Ferri M, Keshishian A, Russ C, Thomas R, Leung G, Emir B, Yuce H, Di Fusco M. Effectiveness and safety of direct oral anticoagulants among nonvalvular atrial fibrillation patients with multimorbidity. *American College of Cardiology (ACC) 70th Annual Scientific Session & Expo*. Atlanta, GA: May 15-17, 2021.
26. Verstovsek S, Yu J, Scherber RM, Verma S, Dieyi C, Chen CC, Parasuraman S. Changes in the incidence and overall survival of patients with myeloproliferative neoplasms between 2002 and 2016 in the United States. *British Society of Haematology 2021 Annual Scientific Meeting (Virtual)*: April 25-28, 2021. (ENCORE presentation, originally presented at *European School of Haematology*)
27. Gandhi K, Ray M, Borra S, Sruti I, Xu L. Prevalence and incidence of vitiligo in the United States: A real-world analysis. *Academy of Managed Care Pharmacy (AMCP) Annual Meeting*. San Francisco, CA: April 13-16, 2021.

28. Huang H, Schmerold L, Dembek C, Fan Q, Dieyi C, Williams GR. Healthcare resource utilization and costs in patients with bipolar disorder treated with lurasidone or cariprazine: A retrospective analysis of insurance claims data. *Academy of Managed Care Pharmacy (AMCP) Annual Meeting*. San Francisco, CA: April 13-16, 2021.
29. Ogbomo A, Tsang Y, Kariburyo F, Jaiswal M, Tsai W, Dufour R, Panjabi S. Real-world analysis of treatment patterns among hospitalized pulmonary arterial hypertension patients. *Academy of Managed Care Pharmacy (AMCP) Annual Meeting*. San Francisco, CA: April 13-16, 2021.
30. Chen J, Nelson DR, Borra S, Liu Y, Maughn K, Fan L, Rey GG, Pollom RD, Hood R. Trajectory of glycosylated hemoglobin over time among obese type 2 diabetes patients on U-100 basal-bolus insulin regimen using real-world data. *ENDO 2021 (Endocrine Society)*. Virtual: March 20-23, 2021.
31. Verstovsek S, Yu J, Scherber RM, Verma S, Dieyi C, Chen CC, Parasuraman S. Changes in the incidence and overall survival of patients with myeloproliferative neoplasms between 2002 and 2016 in the United States. *European School of Haematology: 2nd How to Diagnose and Treat CML / MPN*. Virtual: February 25–28, 2021.
32. Ogbomo A, Tsang Y, Panjabi S, Kariburyo F, Mallampati R, Dufour R. Examining hospitalization and treatment patterns of pulmonary arterial hypertension patients with and without connective tissue disease using real-world data. *Rheumatology Winter Clinical Symposium (RWCS)*. Maui, HI: February 10-13, 2021.
33. Siddiqui MS, Myers J, Byrne C, Wang Y, Tang J, Ogbomo A, Ying Q. Real-world healthcare resource utilization and costs among patients with non-alcoholic fatty liver disease are substantial and increase with advanced disease. *American Association for the Study of Liver Diseases (AASLD) - The Liver Meeting*. San Diego, CA: November 13-17, 2020.
34. Zhuo J, Zhang Q, Knapp K, Wang Y, Gutierrez C, He D, Xie L, Lama S, Craig GL. Risk factors associated with interstitial lung disease in patients with RA: Findings from a retrospective healthcare database analysis. *ACR Convergence 2020 – American College of Rheumatology All-Virtual Annual Meeting*. November 5-9, 2020.
35. Tagawa ST, Sandin R, Sah J, Mu Q, Freedland SJ. Treatment patterns of metastatic castration-sensitive prostate cancer: A real-world evidence study. *European Society for Medical Oncology Virtual Congress 2020*. September 19-21, 2020.
36. Castillo JJ, Yang K, Kariburyo F, Delinger R, Ratiu A, Baser O, Tang B. Clinical and economic burden of mantle cell lymphoma in the Veterans Health Administration population. *Association of VA Hematology/Oncology (AVAHO) 2020 "Virtual" Annual Meeting*, September 12-13, 2020.
37. Castillo JJ, Yang K, Kariburyo F, Delinger R, Ratiu A, Baser O, Tang B. Real-world evidence on treatment patterns, costs and healthcare resource utilization associated with Waldenström macroglobulinemia in the Veterans Health Administration population. *Association of VA Hematology/Oncology (AVAHO) 2020 "Virtual" Annual Meeting*, September 12-13, 2020.
38. Qiu Y, Zhao R, Elpers B, Wang Y, Xie L, Tang J, Fischer A. Prevalence and characteristics of patients receiving antifibrotic therapy for idiopathic pulmonary fibrosis. *European Respiratory Society International Congress 2020*. Vienna, Austria: September 5-9, 2020.
39. Cohen A, Keshishian A, Lee T, Wygant G, Rosenblatt L, Hlavacek P, Sah J, Luo X. Effectiveness and safety of apixaban, low-molecular weight heparin, and warfarin among high-risk subgroups of venous thromboembolism patients with active cancer. *European Society of Cardiology (ESC) Congress 2020*. Amsterdam, The Netherlands: August 29 - September 1, 2020.

40. Huang X, Hovland S, Stange S, Pandya S, Wang L. Real world disease burden, treatment patterns, and outcomes of hospitalized patients with hepatic encephalopathy. *EASL 2020 International Liver Congress*. London, United Kingdom: August 27-29, 2020.
41. Qiu Y, Byrne C, Tang J, Wang Y, Myers J. Use of the Fibrosis-4 score to estimate fibrosis stage for patients with non-alcoholic fatty liver disease/non-alcoholic steatohepatitis in retrospective real-world datasets: A targeted literature review and feasibility assessment. *EASL 2020 International Liver Congress*. London, United Kingdom: August 27-29, 2020.
42. Muser E, Teeple A, Sah J, Wang H, Mallampati R, Xie L. Evaluation of inpatient and emergency room utilization and costs among Crohn's disease patients treated with biologics in three large United States commercial claims databases. *Academy Health 2020 Annual Research Meeting*. Boston, MA: June 13-16, 2020.
43. Muser E, Teeple A, Sah J, Wang H, Mallampati R, Xie L. Concomitant medication utilization among Crohn's disease patients newly initiating biologic therapy from three large commercial insurance claims databases. *Academy Health 2020 Annual Research Meeting*. Boston, MA: June 13-16, 2020.
44. Hood R, Fan L, Pollom RD, Borra S, Huang A, Chen J. Treatment patterns and outcomes before and after human regular U-500 insulin initiation in patients with type 2 diabetes previously on ≤ 200 units/day of insulin. *American Diabetes Association (ADA) 80th Scientific Sessions 2020*. Chicago, IL: June 12-16, 2020.
45. Cazzetta S, Chen G, Pedarla V, Khan QR, Null K, Schwartz D. Economic impact of perianal fistulizing Crohn's disease in US administrative claims data. *American Society of Colon and Rectal Surgeons (ASCRS) Annual Scientific Meeting*. Boston, MA, June 6-10, 2020.
46. Cohen JM, Pandya S, Krasenbaum LJ, Thompson S, Chen CC, Tangirala K. A real-world perspective of patients with episodic migraine or chronic migraine prescribed Ajovy in the United States. *American Headache Society 62nd Annual Scientific Meeting*. San Diego, CA: June 4, 2020.
47. Cohen JM, Pandya S, Tangirala K, Krasenbaum LJ, Chen CC, Thompson S. Treatment patterns and characteristics of patients prescribed AJOVY, Emgality, or Aimovig. *American Headache Society 62nd Annual Scientific Meeting*. San Diego, CA: June 4, 2020.
48. Zhuo J, Zhang Q, Knapp K, Wang Y, Gutierrez C, He D, Xie L, Lama S, Craig G. Examination of interstitial lung disease in patients with rheumatoid arthritis - prevalence, time to onset, and clinical characteristics. *EULAR European Congress of Rheumatology 2020 E-Congress*. June 3-6, 2020.
49. Delinger R, Ratiu A, Xie L, Keshishian A. Assessment of the health care utilization and economic burden on diabetes patients with chronic kidney disease in the US veterans health administration population. *ISPOR 2020*. Orlando, FL: May 16-20, 2020.
50. Li J, Chen CC, Janjan N, Claxton A. Assessment of economic burden and hospitalization on patients with post-traumatic stress disorder in the US veterans health administration population. *ISPOR 2020*. Orlando, FL: May 16-20, 2020.
51. Sah J, Ratiu A, Gutierrez C, Kariburyo MF, Bee G, Xie L. A visual analytical approach to understanding treatment patterns among treatment-naïve rheumatoid arthritis patients with biologic use in the US veterans health administration database. *ISPOR 2020*. Orlando, FL: May 16-20, 2020.
52. Sah J, Ratiu A, Gutierrez C, Kariburyo MF, Bee G, Xie L. A novel visual tool to understand the treatment patterns among treatment-naïve psoriatic arthritis patients prescribed biologics in the US veterans health administration population. *ISPOR 2020*. Orlando, FL: May 16-20, 2020.

53. Bhanegaonkar A, Pandya S, Kim R, Zheng Y, Dieyi C, Krulewicz S, Kasturi V, Liu FX, Hutson TE. IMPACT RCC Real-World Study: Economic Impact of early progression among PATients with metastatic renal cell Carcinoma treated with Tyrosine kinase inhibitors in first-line setting. *ISPOR 2020*. Orlando, FL: May 16-20, 2020.
54. Delinger R, Ratiu A, Xie L, Keshishian A. Comparison of economic burden and risk of hospitalization among HIV patients with and without hepatitis B coinfection in the veterans health administration population. *ISPOR 2020*. Orlando, FL: May 16-20, 2020.
55. Chen J, Fan L, Pollom RD, Borra S, Huang A. Insulin-related out-of-pocket pharmacy costs before and after human regular U-500 insulin initiation via insulin pen in U.S. patients with type 2 diabetes. *ISPOR 2020*. Orlando, FL: May 16-20, 2020.
56. Muser E, Obando C, Teeple A, Bibeau W, Sah J, Mallampati R, Wang H, Xie L. Evaluation of biologic treatment patterns among Crohn's disease patients using three large United States claims databases. *DDW Annual Meeting 2020*. Chicago, IL: May 2-5, 2020.
57. Gutierrez C, Wang H, Sah J, Wang Y, Keshishian A, Xie L. Evaluating the economic burden and hospitalization among patients with inflammatory bowel disease in the US Veterans Health Administration population. *AMCP 2020 Annual Meeting*. Houston, TX: April 21-24, 2020.
58. Palevsky HI, Pruett J, Ogbomo A, Xie L, Mallampati R, Wang H, Dufour R. Examining titration patterns for selexipag in real-world practice using US specialty pharmacy data. *AMCP 2020 Annual Meeting*. Houston, TX: April 21-24, 2020.
59. Delinger R, Keshishian A, Li J, Sah J, Wang Y, Xie L. Assessment of economic burden and hospitalization on patients with human immunodeficiency virus in the US Veterans Health Administration population. *AMCP 2020 Annual Meeting*. Houston, TX: April 21-24, 2020.
60. Shu FI, Treadwell M, Borra S, Shrestha S, Chiao J, Machnig T, Bonagua E, Wang L, Patel AS. Hereditary angioedema and pregnancy complications and outcomes in a population-based cohort. *AAAAI 2020 Annual Meeting*. Philadelphia, PA: March 13-16, 2020.
61. George D, Tagawa S, Lechpammer S, Russell D, Hong A, Mardekian J, Huang A, Wang L, Janjan N, Ramaswamy K. Overall survival (OS) in men with chemotherapy-naïve metastatic castration-resistant prostate cancer (mCRPC) receiving bicalutamide (BIC) followed by enzalutamide (ENZA) or abiraterone (ABI). *ASCO GU 2020*. San Francisco, CA: February 13-15, 2020.
62. Levy M, Xie L, Wang Y, Neumann F, Srivastava S, Naranjo D, Xu J, Zhang Q, Dalal M. Major adverse cardiac, arterial occlusive, and venous occlusive events among chronic myeloid leukemia patients prescribed ponatinib vs bosutinib in a real-world setting. *61st ASH Annual Meeting and Exposition*. Orlando, FL: December 7-10, 2019.
63. Cohen AT, Keshishian A, Lee T, Wygant G, Rosenblatt L, Hlavacek P, Mardekian J, Wiederkehr D, Sah J, Luo X. Safety and effectiveness of apixaban, LMWH and warfarin among venous thromboembolism (VTE) patients with active cancer: A subgroup analysis of VTE risk scale. *61st ASH Annual Meeting and Exposition*. Orlando, FL: December 7-10, 2019.
64. Cohen AT, Keshishian A, Lee T, Wygant G, Rosenblatt L, Hlavacek P, Mardekian J, Wiederkehr D, Sah J, Luo X. Safety and effectiveness of apixaban compared to warfarin among venous thromboembolism patients with active cancer: A retrospective analysis using four US claims databases. *61st American Society of Hematology (ASH) Annual Meeting and Exposition*. Orlando, FL: December 7-10, 2019.
65. Keshishian A, Wiederkehr D, Li X, Mardekian J, Balachander N, Russ C, Rosenblatt L, Dhamane A, Sah J, Luo X. Patterns of oral anticoagulant treatment among non-valvular atrial fibrillation patients with end-stage renal disease treated with dialysis. *American Heart Association (AHA) Scientific Sessions*. Philadelphia, PA: November 16-18, 2019.

66. Phatak H, Zheng Y, Bhanegaonkar A, Kim R, Pandya S, Wang L, Krulewicz S, Kasturi V. Real-world clinical outcomes of patients with metastatic renal cell carcinoma (mRCC) receiving first-line (1L) therapy in the United States (US) veteran population. *18th International Kidney Cancer Symposium (IKCS)*. Miami, FL: November 15-16, 2019.
67. Bhanegaonkar A, Kim R, Pandya S, Wang L, Krulewicz S, Pennock G, Phatak H. Real-world treatment patterns among patients with metastatic renal cell carcinoma receiving first-line therapy in the United States veteran population. *18th International Kidney Cancer Symposium (IKCS)*. Miami, FL: November 15-16, 2019.
68. Nicholls C, Wang Y, Westerbacka J, Wang H, Xie L, Wu J. Examining the temporal trends in hypoglycemia events, treatment adherence and A1c in patients with T2D in the US. *ISPOR Annual European Congress*. Copenhagen, Denmark: November 2-6, 2019.
69. Shrestha S, Wang L, Chen G, Lissos T, Null K. Development and validation of an administrative claims-based inflammatory bowel disease (IBD) severity index. *Academy of Managed Care Pharmacy (AMCP) Nexus 2019*. National Harbor, MD: October 29 - November 1, 2019.
70. Huang Q, Ellis L, Wang L, Shrestha S, Sundaram M. Real-world evidence of ibrutinib use among patients with chronic lymphocytic leukemia and/or small lymphocytic lymphoma in the US Veteran Health Administration population. *Academy of Managed Care Pharmacy (AMCP) Nexus 2019*. National Harbor, MD: October 29 - November 1, 2019.
71. Deitelzweig S, Keshishian A, Kang A, Dhamane A, Luo X, Li X, Balachander N, Rosenblatt L, Mardekian J, Pan X, Di Fusco M, Bassalobre Garcia A, Yuce H, Lip GYH. Effectiveness and safety of apixaban, dabigatran and rivaroxaban versus warfarin in obese patients with nonvalvular atrial fibrillation: ARISTOPHANES subgroup analysis. *14th Annual Cardiometabolic Health Congress*. Chicago, IL: October 10-13, 2019.
72. Patel C, Huang A, Wang L, Paliwal Y, Joshi K. Journey of Veteran Health Administration population with recent schizophrenia diagnosis: A real-world analysis of treatment patterns and healthcare burden. *32nd Annual Psych Congress*. San Diego, CA: October 3-6, 2019.
73. Ng-Mak D, Kadakia A, Shrestha S, Wang L, Loebel A. Hospitalization risk in pediatric bipolar patients treated with lurasidone vs. other oral atypical antipsychotics: A real-world retrospective claims database study. *32nd Annual Psych Congress*. San Diego, CA: October 3-6, 2019.
74. Kambhampati S, Parasuraman S, Yu J, Paraganama D, Shrestha S, Wang L, Baser O, Scherber R. Hematocrit (HCT) levels and thrombotic events (TEs) among US veterans with polycythemia vera (PV). *Association of VA Hematology/Oncology (AVAHO) Annual Meeting 2019*. Minneapolis, MN: September 20-22, 2019.
75. Huang Q, Ellis L, Wang L, Shrestha S, Sundaram M. First-line ibrutinib treatment is associated with longer time to next treatment in a real-world US veterans population. *Society of Hematologic Oncology (SOHO) 2019 Annual Meeting*. Houston, TX: September 11-14, 2019.
76. Deitelzweig S, Keshishian A, Kang A, Dhamane A, Luo X, Li X, Balachander N, Rosenblatt L, Mardekian J, Jiang J, Di Fusco M, Reeves ABG, Yuce H, Lip GYH. Comparative effectiveness and safety between non-VKA oral anticoagulants in non-valvular atrial fibrillation patients with differential duration of treatment: an analysis of the ARISTOPHANES study. *European Society of Cardiology (ESC) Congress 2019*. Paris, France: August 31 - September 1, 2019.
77. Deitelzweig S, Keshishian A, Kang A, Dhamane A, Luo X, Li X, Balachander N, Rosenblatt L, Mardekian J, Jiang J, Di Fusco M, Reeves ABG, Yuce H, Lip GYH. Comparative effectiveness and safety of non-VKA oral anticoagulants versus warfarin in non-valvular atrial fibrillation patients with differential treatment duration: An ARISTOPHANES study analysis. *European Society of Cardiology (ESC) Congress 2019*. Paris, France: August 31 - September 1, 2019.

78. Keshishian A, Lee T, Wygant G, Rosenblatt L, Hlavacek P, Mardekian J, Wiederkehr D, Sah J, Sun X, Luo X. Patterns of extended apixaban treatment for unprovoked venous thromboembolism in routine clinical practice. *European Society of Cardiology (ESC) Congress 2019*. Paris, France: August 31 - September 1, 2019.
79. Neslusan C, Huang A, John J. Sheehan JJ, Wang L. Characteristics of the Veterans Health Administration population diagnosed with major depressive disorder and suicidal ideation or suicide attempt. *2019 VA/DoD Suicide Prevention Conference*. Nashville, TN: August 26-29, 2019.
80. Keshishian A, Lee T, Wygant G, Rosenblatt L, Hlavacek P, Mardekian J, Wiederkehr D, Sah J, Qiang W, Luo X. Anticoagulant treatment patterns among venous thrombosis patients with active cancer: a retrospective analysis using four US claims databases. *27th International Society on Thrombosis and Hemostasis (ISTH) Congress and 65th Annual Scientific Meeting 2019*. Melbourne, Australia: July 6-10, 2019.
81. Xie L, Kariburyo F, Sah J, Lofland JH, Li N. Real world medication use in incident systemic lupus erythematosus and lupus nephritis patients. *European Congress of Rheumatology (EULAR) 2019*. Madrid, Spain: June 12-15, 2019.
82. Neslusan C, Sheehan JJ, Wang L, Huang A. Characteristics of the Veterans Health Administration population diagnosed with major depressive disorder and suicidal ideation or suicide attempt. *American Society of Health-System Pharmacists (ASHP) Summer Meetings & Exhibition*. Boston, MA: June 8-12, 2019.
83. Chen J, Fan L, Juneja R, Borra S, Huang A, Wang L. Treatment patterns and outcomes before and after human regular U-500 insulin initiation via kwikpen in US veterans with type 2 diabetes. *American Diabetes Association (ADA) 79th Scientific Sessions*. San Francisco, CA: June 7-11, 2019.
84. Zheng Y, Pandya S, Yu T, Kearney M, Wang L, Kim R, Phatak H. Real-world clinical and economic outcomes among newly-diagnosed merkel cell carcinoma (MCC) patients starting checkpoint inhibitors (CPIs) or chemotherapy (CT) in the Veterans Health Administration (VHA). *American Society of Clinical Oncology (ASCO) 2019 Annual Meeting*. Chicago, IL: May 31 - June 4, 2019.
85. Mavros P, Patel C, El Khoury A, Huang A, Wang L, Bashyal R. A real-world analysis of outcomes related to veterans with schizophrenia who transitioned to once-every-3-months paliperidone palmitate vs those who remained on once-monthly paliperidone palmitate. *American Society of Clinical Psychopharmacology (ASCP) Annual Meeting 2019*. Scottsdale, AZ: May 28-31, 2019.
86. Bhanegaonkar A, Kim R, Pandya S, Krulewicz S, Wang L, Pennock G, Phatak H. Real-world treatment patterns among metastatic urothelial cancer patients receiving second-line therapy in the US veteran population. *International Society of Pharmacoeconomics and Outcomes Research (ISPOR) 2019 Annual Meeting*. New Orleans, LA: May 18-22, 2019.
87. Okunowo O, Li L, Pedarla V, Gu Y, Wang L, Baser O. Assessing the economic burden and predictors of hospitalization among US veteran patients with rheumatoid arthritis: A retrospective case-control study. *ISPOR US Annual Meeting*. New Orleans, LA: May 18-22, 2019.
88. Pan X, Chen CC, Wang L, Yuce H, Baser O. Real-world evidence of the economic burden and risk factors for hospitalization among patients with myeloma in the US Veterans Health Administration population. *ISPOR US Annual Meeting*. New Orleans, LA: May 18-22, 2019.
89. Obando C, Ding Z, Muser E, Vaidya N, Qiang W, Sun X, Wang H, Mallampati R, Xie L. Evaluation of ustekinumab treatment patterns among Crohn's disease patients in three large US commercial claims databases. *Digestive Disease Week (DDW)*. San Diego, CA: May 18-21, 2019.

90. Pennock G, Wang L, Pandya S. Real-world treatment patterns among metastatic renal cell carcinoma patients receiving first-line therapy in the United States veteran population. *ISPOR US Annual Meeting*. New Orleans, LA: May 18-22, 2019.
91. Lim S, Johnston S, Wang Y, Roy S, Shen Y, Huang T, Kassis E. Evaluation of clinical and economic outcomes associated with staple line buttress among patients undergoing sleeve gastrectomy. *ISPOR US Annual Meeting*. New Orleans, LA: May 18-22, 2019.
92. Obando C, Ding Z, Muser E, Vaidya N, Qiang W, Sun X, Wang H, Mallampati R, Xie L. Evaluation of health care utilization, hospitalization/emergency room costs, and other medication use among Crohn's disease patients using ustekinumab in three large United States commercial claims databases. *Digestive Disease Week (DDW)*. San Diego, CA: May 18-21, 2019.
93. Zhang Q, Delinger R, Wang H, Wang Y, Yuce H, Baser O, Xie L. Assessing the risk factors of heart failure among patients in the US Department of Defense population. *ISPOR US Annual Meeting*. New Orleans, LA: May 18-22, 2019.
94. Dieyi C, Pedarla V, Gu Y, Liu Y, Li L, Wang L, Yuce H, Baser O. Assessing the economic burden and hospitalization among patients with non-alcoholic steatohepatitis in the US Veterans Health Administration population. *ISPOR US Annual Meeting*. New Orleans, LA: May 18-22, 2019.
95. Samuelsen C, Lim J, Golembesky AK, Shrestha S, Wang L, Griebisch I. Retrospective claims analysis of treatment duration, healthcare resource utilization and costs associated with first-line treatment of NSCLC with afatinib vs erlotinib in the United States. *ISPOR US Annual Meeting*. New Orleans, LA: May 18-22, 2019.
96. Neslusan C, Sheehan J, Wang L, Huang A. Characteristics of the Veterans Health Administration population diagnosed with major depressive disorder and suicidal ideation or suicide attempt. *American Psychiatric Association (APA) Annual Meeting*. San Francisco, CA: May 18-22, 2019.
97. Wang H, Qiang W, Delinger R, Keshishian A, Yuce H, Baser O, Xie L. Examining the risk factors of chronic obstructive pulmonary disease among patients in the Department of Defense population. *ISPOR US Annual Meeting*. New Orleans, LA: May 18-22, 2019.
98. Cole M, Lickert C, Drake W, Xie L, Leber L, Yuce H. Baseline demographics and clinical characteristics of chronic thromboembolic pulmonary hypertension patients within the Medicare population. *American Thoracic Society (ATS) International Conference 2019*. Dallas, TX: May 17-22, 2019.
99. Wang Y, Zhang Q, Xie L, Dembek C, Kamble P, Ganapathy V. Overuse of short-acting bronchodilators and the risk of exacerbation among patients with chronic obstructive pulmonary disease (COPD) treated with nebulized short-acting bronchodilators. *American Thoracic Society (ATS) International Conference 2019*. Dallas, TX: May 17-22, 2019.
100. Keshishian A, Li X, Hamilton M, Masseria C, Dhamane A, Luo X, Mardekian J, Friend K, Nadkarni A, Pan X, Baser O, Lip GYH. Comparative effectiveness and safety of non-vitamin K antagonist oral anticoagulants versus warfarin in non-valvular atrial fibrillation patients: The dose subgroup analysis of the ARISTOPHANES study. *71st American Academy of Neurology (AAN) Annual Meeting*. Philadelphia, PA: May 4-10, 2019.
101. Thieffry S, Borghs S, Wang L, Shrestha S, Foskett N. Characteristics, healthcare resource use and costs of overall pediatric focal epilepsy population and by comorbidity subgroup: A US claims database analysis. *71st American Academy of Neurology (AAN) Annual Meeting*. Philadelphia, PA: May 4-10, 2019.
102. Freedland SJ, Ramaswamy K, Lechpammer S, Mardekian J, Schultz NM, Huang A, Wang L, Baser O, George D. Impact of prostate specific antigen doubling time on metastasis and increased costs associated with progression to metastatic castrate-resistant prostate cancer. *2019 Annual Meeting of the American Urological Association (AUA) Education and Research Inc*. Chicago, IL: May 3-6, 2019.

103. Ramaswamy K, Lechpammer S, Mardekian J, Schultz NM, Huang A, Wang L, Baser O, George D. Survival rates and economic outcomes in chemotherapy-naïve metastatic castrate resistant prostate cancer patients treated with abiraterone acetate or enzalutamide. *2019 Annual Meeting of the American Urological Association (AUA) Education and Research Inc.* Chicago, IL: May 3-6, 2019.
104. Xie L, Kariburyo F, Sah J, Lofland JH, Li N. Real world medication use in Incident systemic lupus erythematosus and lupus nephritis patients. *Congress of Clinical Rheumatology – East 2019.* Destin, FL: May 2-5, 2019.
105. Patel C, El Khoury A, Huang A, Wang L, Bashyal R. A real-world analysis of transitioning from oral risperidone or paliperidone to once-monthly paliperidone palmitate among veterans with schizophrenia. *22nd Annual Meeting of the College of Psychiatric and Neurologic Pharmacists (CPNP).* Salt Lake City, UT: April 7-10, 2019.
106. Hlavacek P, Guo JD, Rosenblatt L, Keshishian A, Russ C, Mardekian J, Ferri M, Poretta T, Yuce H, McBane R. Effectiveness and safety of apixaban compared to warfarin among VTE patients in the US Medicare population. *American Heart Association (AHA) QCOR 2019.* Arlington, VA: April 5-6, 2019.
107. El Khoury A, Patel C, Huang A, Wang L, Bashyal R. Real-world outcomes among veterans severely affected by schizophrenia that transitioned from oral risperidone or paliperidone to once-monthly paliperidone palmitate. *Academy of Managed Care Pharmacy (AMCP) Annual Meeting.* San Diego, CA: March 25-28, 2019.
108. Hlavacek P, Guo JD, Rosenblatt L, Keshishian A, Russ C, Mardekian J, Ferri M, Poretta T, Yuce H, McBane R. Comparison of costs among VTE patients initiating apixaban or warfarin in the US Medicare population. *Academy of Managed Care Pharmacy (AMCP) Annual Meeting.* San Diego, CA: March 25-28, 2019.
109. Pedarla V, Gu Y, Wang L, Baser O. Health care utilization and economic burden of type-2 diabetes among patients in the US Department of Defense population. *Academy of Managed Care Pharmacy (AMCP) Annual Meeting.* San Diego, CA: March 25-28, 2019.
110. Zhang Q, Delinger R, Fang B, Wang Y, Xie L. Health care utilization and economic burden of multiple myeloma among patients in the US Department of Defense population. *Academy of Managed Care Pharmacy (AMCP) Annual Meeting.* San Diego, CA: March 25-28, 2019.
111. Qiang W, Fang B, Delinger R, Keshishian A, Xie L. Health care utilization and economic burden of type-2 diabetes among patients in the US Department of Defense population. *Academy of Managed Care Pharmacy (AMCP) Annual Meeting.* San Diego, CA: March 25-28, 2019.
112. Pedarla V, Gu Y, Wang L, Baser O. Assessing economic burden and hospitalization among asthma patients in the US Veterans Health Administration population. *Academy of Managed Care Pharmacy (AMCP) Annual Meeting.* San Diego, CA: March 25-28, 2019.
113. Pavilack M, Narendranath E, Andritsos L, Bashyal R, Olufade T. Healthcare costs and resource utilization associated with adverse events among hairy cell leukemia patients treated with purine nucleoside analogs. *National Comprehensive Cancer Network (NCCN) 2019 Annual Conference.* Orlando, FL: March 21-23, 2019.
114. Lip GYH, Keshishian A, Kang A, Dhamane A, Luo X, Li X, Balachander N, Rosenblatt L, Mardekian J, Pan X, Di Fusco M, Bassalobre Garcia A, Yuce H, Deitelzweig S. Comparative effectiveness and safety of non-vitamin K antagonist oral anticoagulants among frail nonvalvular atrial fibrillation patients. *American College of Cardiology's 68th Annual Scientific Session & Expo.* New Orleans, LA: March 16-18, 2019.

115. Chowdhury R, Franchino-Elder J, Wang L, Yuce H, Wang C. Health care resource utilization and expenditures among newly diagnosed non-valvular atrial fibrillation patients initiating oral anticoagulants: Results from 100% Medicare 2010-2015 data. *American College of Cardiology's (ACC) 68th Annual Scientific Session & Expo*. New Orleans, LA: March 16-18, 2019.
116. Deitelzweig S, Keshishian A, Kang A, et al. Effectiveness and safety of non-vitamin K antagonist oral anticoagulants in obese non-valvular atrial fibrillation patients: A pooled claims database analysis. *American College of Cardiology's (ACC) 68th Annual Scientific Session & Expo*. New Orleans, LA: March 16-18, 2019.
117. Deitelzweig S, Keshishian A, Kang A, et al. Effectiveness and safety of apixaban, dabigatran, and rivaroxaban versus warfarin in obese patients with non-valvular atrial fibrillation: ARISTOPHANES subgroup analysis. *American College of Cardiology's (ACC) 68th Annual Scientific Session & Expo*. New Orleans, LA: March 16-18, 2019.
118. Deitelzweig S, Keshishian A, Kang A, Dhamane A, Luo X, Li X, Balachander N, Rosenblatt L, Mardekian J, Pan X, Di Fusco M, Bassalobre Garcia A, Yuce H, Lip GYH. Effectiveness and safety of non-vitamin K antagonist oral anticoagulants in obese nonvalvular atrial fibrillation patients: A pooled claims database analysis. *American College of Cardiology's 68th Annual Scientific Session & Expo*. New Orleans, LA: March 16-18, 2019.
119. Lip GYH, Keshishian A, Kang A, Dhamane A, Luo X, Li X, Balachander N, Rosenblatt L, Mardekian J, Pan X, Di Fusco M, Bassalobre Garcia A, Yuce H, Deitelzweig S. Effectiveness and safety of non-vitamin K antagonist oral anticoagulants compared to warfarin among frail nonvalvular atrial fibrillation patients. *American College of Cardiology's 68th Annual Scientific Session & Expo*. New Orleans, LA: March 16-18, 2019.
120. Deitelzweig S, Keshishian A, Kang A, Dhamane A, Luo X, Li X, Balachander N, Rosenblatt L, Mardekian J, Pan X, Di Fusco M, Bassalobre Garcia A, Yuce H, Lip GY. Effectiveness and safety of apixaban, dabigatran and rivaroxaban versus warfarin in obese patients with nonvalvular atrial fibrillation: ARISTOPHANES subgroup analysis. *American College of Cardiology's 68th Annual Scientific Session & Expo*. New Orleans, LA: March 16-18, 2019.
121. Parasuraman S, Yu J, Paranagama D, Shrestha S, Wang L, Baser O, Scherber R. Elevated white blood cell levels and thrombotic events in patients with polycythemia vera: A real-world analysis of Veterans Health Administration data. *European School of Haematology: How to Diagnose and Treat CML/MPN*. Saggart, Ireland: March 8-10, 2019.
122. Armstrong AW, Gadkari A, Mallya UG, Miao R, Shrestha S, Wang L, Kaur M. The economic burden associated with time to therapy escalation for patients with atopic dermatitis uncontrolled with topical therapies. *American Academy of Dermatology (AAD) Annual Meeting*. Washington, DC: March 1-5, 2019.
123. Freedland SJ, Ramaswamy K, Lechpammer S, Mardekian J, Schultz NM, Huang A, Wang L, Baser O, George D. Impact of prostate specific antigen doubling time on time to metastasis and overall survival in non-metastatic castration-resistant prostate cancer patients. *American Society of Clinical Oncology-Genitourinary Cancers Symposium*. San Francisco, CA: February 14-16, 2019.
124. Zheng Y, Pandya S, Yu T, Kearney M, Shrestha S, Wang L, Kim R, Phatak H. Emerging treatment patterns and checkpoint inhibitor use among newly-diagnosed merkel cell carcinoma patients in the US veteran population. *ASCO-SITC Clinical Immuno-Oncology Symposium*. San Francisco, CA: February 8 - March 2, 2019.
125. Dahhan T, Cole M, Lickert C, Xie L, Leber L, Yuce H, Fares WH, Drake W. Baseline demographics and clinical characteristics of chronic thromboembolic pulmonary hypertension patients within Medicare population. *13th Pulmonary Vascular Research Institute (PVRI) Annual World Congress on Pulmonary Vascular Disease (PVD)*. Barcelona, Spain: January 30 - February 3, 2019.

126. Levy M, Xie L, Wang Y, Neumann F, Srivastava S, Naranjo D, Zhang Q, Dalal M. Real-world comparisons of cardiovascular events between different tyrosine kinase inhibitors among patients with chronic myeloid leukemia. *American Society of Hematology (ASH) Annual Meeting*. San Diego, CA: December 1-4, 2018.
127. Parasuraman S, Baser O, Sturm D, Wang L, Shrestha S. Elevated white blood cell levels and thrombotic events in patients with polycythemia vera: A real-world analysis of Veterans Health Administration data. *American Society of Hematology (ASH) Annual Meeting*. San Diego, CA: December 1-4, 2018.
128. Epperla N, Pavilack M, Olufade T, Bashyal R, Li J, Yuce H, Andritsos L. Adverse events among patients with hairy cell leukemia treated with purine nucleoside analogs in the United States. *American Society of Hematology (ASH) Annual Meeting*. San Diego, CA: December 1-4, 2018.
129. Pandya S, Clancy Z, Shrestha S, Wang L, Baser O. Burden of CRAB events by relapse in patients with newly diagnosed multiple myeloma not eligible for stem cell transplant. *American Society of Hematology (ASH) Annual Meeting*. San Diego, CA: December 1-4, 2018.
130. Borra S, Lin C, Wang L, Yuce H, Baser O. Assessing the economic burden and 30-day readmission rates among patients with bladder cancer in the US Veterans Health Administration population. *International Society of Pharmacoeconomics and Outcomes Research (ISPOR) Europe 2018*. Barcelona, Spain: November 10-14, 2018.
131. Lip GHY, Keshishian A, Li X, Dhamane A, Luo X, Balachander N, Rosenblatt L, Mardekian J, Pan X, Nadkarni A, Garcia AB, Di Fusco M, Yuce H, Deitelzweig S. Non-vitamin K antagonist oral anticoagulants associated with lower stroke rates compared to warfarin among very elderly patients with non-valvular atrial fibrillation: An ARISTOPHANES subgroup analysis. *American Heart Association (AHA) Scientific Sessions 2018*. Chicago, IL: November 10-12, 2018.
132. Lip GYH, Keshishian A, Li X, et al. Effectiveness and safety of non-vitamin K antagonist oral anticoagulants among very elderly patients with non-valvular atrial fibrillation: An observational study. *American Heart Association (AHA) Scientific Sessions 2018*. Chicago, IL: November 10-12, 2018.
133. Deitelzweig S, Keshishian A, Li X, Dhamane A, Luo X, Balachander N, Rosenblatt L, Mardekian J, Pan X, Nadkarni A, Di Fusco M, Garcia AB, Yuce H, Lip GYH. Effectiveness and safety of novel oral anticoagulants among patients with nonvalvular atrial fibrillation and diabetes: A pooled claims database analysis. *American Heart Association (AHA) Scientific Sessions 2018*. Chicago, IL: November 10-12, 2018.
134. Deitelzweig S, Keshishian A, Li X, Dhamane A, Luo X, Balachander N, Rosenblatt L, Mardekian J, Pan X, Nadkarni A, Di Fusco M, Garcia AB, Yuce H, Lip GYH. Comparative effectiveness and safety of non-vitamin K antagonist oral anticoagulants versus warfarin among patients with non-valvular atrial fibrillation and diabetes: ARISTOPHANES diabetes subgroup analysis. *American Heart Association (AHA) Scientific Sessions 2018*. Chicago, IL: November 10-12, 2018.
135. Xie L, Sun X, Mallampati R, Wang Y, Yuce H, Baser O. Healthcare utilization and economic burden on patients with bladder cancer in the US Department of Defense population. *International Society of Pharmacoeconomics and Outcomes Research (ISPOR) Europe 2018*. Barcelona, Spain: November 10-14, 2018.
136. Szukis H, Benson C, Huang A, Amos TB, Wang L, Baser O. Economic burden of illness among US veterans with treatment-resistant depression. *US Psych Congress 2018*. Orlando, FL: October 25-28, 2018.
137. Patel C, El Khoury A, Huang A, Wang L, Baser O, Joshi K. Outcomes Related to transition to once-every-three-monthly paliperidone palmitate among veterans with schizophrenia. *US Psych Congress 2018*. Orlando, FL: October 25-28, 2018.

138. George D, Schultz N, Huang A, Wang L, Baser O, Ramaswamy K, Mardekian J. Increased costs associated with progression to metastatic castrate-resistant prostate cancer. *Academy of Managed Care Pharmacy (AMCP) Nexus 2018*. Orlando, FL: October 22-25, 2018.
139. Ramaswamy K, Mardekian J, Schultz N, Huang A, Wang L, Baser O, George D. Economic burden of chemotherapy naïve metastatic castrate resistant prostate cancer patients treated with abiraterone acetate or enzalutamide in the United States. *Academy of Managed Care Pharmacy (AMCP) Nexus 2018*. Orlando, FL: October 22-25, 2018.
140. Amin A, Keshishian A, Dina O, Dhamane A, Nadkarni A, Carda E, Russ C, Rosenblatt L, Yuce H, Baker C. Elderly patients with non-valvular atrial fibrillation incurred lower all-cause, stroke, and major bleeding-related costs when treated with apixaban versus dabigatran, rivaroxaban, and warfarin treatment. *Academy of Managed Care Pharmacy (AMCP) Nexus 2018*. Orlando, FL: October 22-25, 2018.
141. Amin A, Keshishian A, Dina O, Dhamane A, Nadkarni A, Carda E, Russ C, Rosenblatt L, Yuce H, Baker C. Healthcare costs of direct oral anticoagulants vs warfarin among Medicare patients with non-valvular atrial fibrillation. *Academy of Managed Care Pharmacy (AMCP) Nexus 2018*. Orlando, FL: October 22-25, 2018.
142. Xie L, Kariburyo F, Sah J, Lofland JH, Li N. Real-world medication use in incident systemic lupus erythematosus and lupus nephritis patients. *American College of Rheumatology (ACR) / ARHP Annual Meeting*. Chicago, IL: October 19-24, 2018.
143. Katz NP, Gandhi K, Wei W, Huang A, Wang L. Assessing inappropriate pain management in adults with hip or knee osteoarthritis treated with different opioid intensity regimens: Results from a retrospective database analysis. *American College of Rheumatology (ACR) / ARHP Annual Meeting*. Chicago, IL: October 19-24, 2018.
144. Bhor M, Xie L, Arcona S, Paulose J, Yuce H, Shah N. Rate of vaso-occlusive crisis episodes among sickle cell disease patients in the US Medicaid population. *Sickle Cell Disease Association of America (SCDAA) 46th Annual National Convention for Sickle Cell Disease*. Baltimore, MD: October 10-13, 2018.
145. Bhor M, Xie L, Paulose J, Yuce H, Shah N. Primary reasons for sickle-cell disease-related hospital and emergency room visits in the US Medicaid population. *Sickle Cell Disease Association of America (SCDAA) 46th Annual National Convention for Sickle Cell Disease*. Baltimore, MD: October 10-13, 2018.
146. Pandya S, Shrestha S, Wang L, Baser O, Clancy Z, Ni Q. Real-world economic outcomes of early progression in newly diagnosed multiple myeloma (NDMM) patients (Pts). *2018 American Society of Clinical Oncology (ASCO) Quality Care Symposium*. Phoenix, AZ: September 28-29, 2018.
147. Katz NP, Wei W, Gandhi K, Huang A, Wang L. A real-world study of treatment regimen failure by opioid use intensity among patients with hip and/or knee osteoarthritis (OA). *International Association for the Study of Pain (IASP) The 17th World Congress on Pain*. Boston, MA: September 12-16, 2018.
148. Amin A, Bassalobre Garcia A, Li X, Dhamane A, Luo X, Di Fusco M, Nadkarni A, Friend K, Rosenblatt L, Mardekian J, Pan X, Baser O, Keshishian A. Comparison of effectiveness, safety, and healthcare costs in nonvalvular atrial fibrillation patients with heart failure prescribed direct oral anticoagulants. *European Society of Cardiology (ESC) Congress 2018*. Munich, Germany: August 25-29, 2018.
149. Lip GYH, Keshishian A, Li X, Hamilton M, Masseria C, Dhamane A, Luo X, Mardekian J, Friend K, Nadkarni A, Pan X, Baser O, Deitelzweig S. Comparative effectiveness and safety between non-VKA oral anticoagulants in non-valvular atrial fibrillation patients: a dose subgroup analysis of the ARISTOPHANES study. *European Society of Cardiology (ESC) Congress 2018*. Munich, Germany: August 25-29, 2018.

150. Deitelzweig S, Keshishian A, Li X, Hamilton M, Masseria C, Dhamane A, Luo X, Mardekian J, Friend K, Nadkarni A, Pan X, Baser O, Lip GYH. Comparisons of clinical and economic outcomes between non-VKA oral anticoagulants among non-valvular atrial fibrillation patients: the ARISTOPHANES study. *European Society of Cardiology (ESC) Congress 2018*. Munich, Germany: August 25-29, 2018.
151. Lip GYH, Keshishian A, Li X, Hamilton M, Masseria C, Dhamane A, Luo X, Mardekian J, Friend K, Nadkarni A, Pan X, Baser O, Deitelzweig S. Comparisons of clinical and economic outcomes between non-VKA oral anticoagulants and warfarin among non-valvular atrial fibrillation patients: the ARISTOPHANES study. *European Society of Cardiology (ESC) Congress 2018*. Munich, Germany: August 25-29, 2018.
152. Amin A, Keshishian A, Zhang Q, Dina O, Dhamane A, Nadkarni A, Carda E, Liu X, Rosenblatt L, Baser O, Baker C. Effectiveness, safety, and composite clinical outcomes between apixaban and other oral anticoagulants for non-valvular atrial fibrillation patients in the US Medicare population. *European Society of Cardiology (ESC) Congress 2018*. Munich, Germany: August 25-29, 2018.
153. Deitelzweig S, Keshishian A, Li X, Hamilton M, Masseria C, Dhamane A, Luo X, Mardekian J, Friend K, Nadkarni A, Pan X, Baser O, Lip GYH. Comparative effectiveness and safety of non-vitamin K antagonist oral anticoagulants versus warfarin in non-valvular atrial fibrillation patients: the dose subgroup analysis of the ARISTOPHANES study. *European Society of Cardiology (ESC) Congress 2018*. Munich, Germany: August 25-29, 2018.
154. Amin A, Keshishian A, Zhang Q, Dina O, Dhamane A, Nadkarni A, Carda E, Liu X, Rosenblatt L, Baser O, Baker C. Effectiveness, safety, and composite clinical outcomes of apixaban, dabigatran, rivaroxaban, relative to warfarin in non-valvular atrial fibrillation patients in the US Medicare population. *European Society of Cardiology (ESC) Congress 2018*. Munich, Germany: August 25-29, 2018.
155. Lopes RD, Steffel J, Di Fusco M, Keshishian A, Luo X, Li X, Masseria C, Hamilton M, Friend K, Gupta K, Mardekian J, Pan X, Baser O, Jones WS. Standard and reduced doses of direct oral anticoagulants versus warfarin in elderly patients with non-valvular atrial fibrillation and concomitant coronary artery disease or peripheral artery disease. *European Society of Cardiology (ESC) Congress 2018*. Munich, Germany: August 25-29, 2018.
156. Lopes RD, Steffel J, Di Fusco M, Keshishian A, Luo X, Li X, Masseria C, Hamilton M, Friend K, Gupta K, Mardekian J, Pan X, Baser O, Schuyler Jones W. Effectiveness and safety of direct oral anticoagulants versus warfarin in elderly patients with non-valvular atrial fibrillation according to coronary artery disease and/or peripheral artery disease. *European Society of Cardiology (ESC) Congress 2018*. Munich, Germany: August 25-29, 2018.
157. Amin A, Bassalobre Garcia A, Li X, Dhamane A, Luo X, Di Fusco M, Nadkarni A, Friend K, Rosenblatt L, Mardekian J, Pan X, Baser O, Keshishian A. Comparison of effectiveness, safety, and healthcare costs of direct oral anticoagulants with warfarin in non-valvular atrial fibrillation patients with heart failure. *European Society of Cardiology (ESC) Congress 2018*. Munich, Germany: August 25-29, 2018.
158. Cohen J, Beaubrun A, Bashyal R, Huang A, Huang T, Baser O. Real-world persistence for newly prescribed HIV-1 treatment: Single versus multiple tablet regimen comparison. *34th International Conference on Pharmacoepidemiology & Therapeutic Risk Management (ICPE)*. Prague, Czech Republic: August 22-26, 2018.
159. Coleman CI, Herman WH, Pandya S, Wang L, Baser O, Cai J, Bookhart B. Body Weight (BW) Outcomes with Canagliflozin 300 mg (CANA) vs. Glucagon-Like Peptide-1 Receptor Agonists (GLP-1s) in a Real-World (RW) Setting. *American Diabetes Association (ADA) 78th Scientific Sessions*. Orlando, FL: June 22-26, 2018.
160. Rubin DT, Long MD, Keshishian A, Baser O, Hepp Z, Wang A. The impact of intestinal complications on healthcare costs among inflammatory bowel disease patients with anti-TNF therapies. *Digestive Disease Week (DDW)*. Washington, DC: June 2-5, 2018.

161. Obando C, Xie L, Vaidya N, Sah J. Evaluate the treatment patterns and healthcare utilizations for biologic therapies for Crohn's disease. *Digestive Disease Week*. Washington, DC: June 2-5, 2018.
162. Pandya S, Clancy Z, Shrestha S, Wang L, Ni Q, Baser O. Economic burden of early progression in newly-diagnosed multiple myeloma patients. *2018 American Society of Clinical Oncology (ASCO) Annual Meeting*. Chicago, IL: June 1-5, 2018.
163. Gupta A, Lin C, Wang L, Yuce H, Aygenc G, Baser O. Assessing the economic burden and 30-day readmission rates among patients with chronic obstructive pulmonary disease in the US Veterans Health Administration population. *International Society of Pharmacoeconomics and Outcomes Research (ISPOR) 23rd International Meeting*. Baltimore, MD: May 19-23, 2018.
164. Bhor M, Wang Y, Xie L, Halloway R, Arcona S, Paulose J, Ogbomo A, Shen Y, Yuce H, Shah N. Relationship between pain crisis and life-threatening complications in sickle cell disease: A retrospective claims based study. *International Society of Pharmacoeconomics and Outcomes Research (ISPOR) 23rd International Meeting*. Baltimore, MD: May 19-23, 2018.
165. Xie L, Wang Y, Qiang W, Sah J, Yuce H, Aygenc G, Baser O. Health care utilization and economic burden of patients with inflammatory bowel disease in the US Department of Defense population. *International Society of Pharmacoeconomics and Outcomes Research (ISPOR) 23rd International Meeting*. Baltimore, MD: May 19-23, 2018.
166. Bhor M, Wang Y, Xie L, Halloway R, Arcona S, Paulose J, Ogbomo A, Shen Y, Yuce H, Shah N. Poor medication adherence and high rates of treatment discontinuation among SCD patients treated with hydroxyurea. *International Society of Pharmacoeconomics and Outcomes Research (ISPOR) 23rd International Meeting*. Baltimore, MD: May 19-23, 2018.
167. Parasuraman S, Yu J, Paranagama D, Shrestha S, Wang L, Baser O, Scherber R. Hematocrit (HCT) Levels and Thrombotic Events (TEs) Among US Veterans with Polycythemia Vera (PV). *European School of Haematology (ESH) International Conference on Myeloproliferative Neoplasm*. Saggart, Ireland: May 15-17, 2018.
168. Bhor M, Wang Y, Xie L, Halloway R, Arcona S, Paulose J, Ogbomo A, Shen Y, Yuce H, Shah N. Clinical burden and management of sickle cell disease among pediatric patients. *The 2018 American Society of Pediatric Hematology/Oncology (ASPHO) Conference*. Pittsburgh, PA: May 2-5, 2018.
169. Huang A, Wei W, Gandhi K, Wang L, Inguva S, Katz NP. Opioid use intensity and its association with opioid overdose risk and abuse and hospitalization among patients with hip/knee osteoarthritis: A retrospective analysis of real-world data. *American Academy of Pain Medicine's (AAPM) 34th Annual Meeting*. Vancouver, Canada: April 26-29, 2018.
170. Xie L, Baser O, Wang Y, Qiang W, Shen Y. Health Care Utilization and Economic Burden on Patients Diagnosed with Epilepsy in the US Department of Defense Population. *Academy of Managed Care Pharmacy (AMCP) Annual Meeting 2018*. April 23-26, 2018: Boston, MA.
171. O'Neal W, Mendes S, Baser O, Wang L, Cramer J. Adherence and outpatient resource use with extended-release oxcarbazepine (Oxtellar XR®) vs immediate-release oxcarbazepine (OXC-IR): Analysis of pooled data from four national claims databases. *Academy of Managed Care Pharmacy (AMCP) Annual Meeting 2018*. Boston, MA: April 23-26, 2018.
172. Borra S, Lin C, Wang L, Baser O. Assessing the Economic Burden and 30-Day Readmission Rates Among Patients with Breast Cancer in the US Veterans Health Administration Population. *Academy of Managed Care Pharmacy (AMCP) Annual Meeting 2018*. Boston, MA: April 23-26, 2018.

173. Fishman J, Shrestha S, Wang L, Yuce H, Zorzoli J, Faught E, Farley J. Impact of Medicaid antiepileptic drug formulary restrictions on health outcomes and costs. *2018 American Academy of Neurology (AAN) Annual Meeting*. Los Angeles, CA: April 21-27, 2018.
174. Deitelzweig S, Keshishian A, Li X, Hamilton M, Masseria C, Gupta K, Luo X, Mardekian J, Friend K, Nadkarni A, Pan X, Baser O, Lip GYH. Comparison of effectiveness, safety, and the net clinical outcome between different direct oral anticoagulants in 162,707 non-valvular atrial fibrillation patients treated in US clinical practice. *American College of Cardiology (ACC) 67th Annual Scientific Session & Expo*. Orlando, FL: March 10-12, 2018.
175. Pandya S, Wang L, Baser O, Wan G, Lovelace B, Potenziano J, Pham AT, Kontekakis A, Huang X. The burden of hypoxic respiratory failure in preemies and neonates in the United States: 2011-2015. *Hot Topics in Neonatology*. Washington, DC: December 11-13, 2017.
176. Huntington S, Keshishian A, Xie L, Baser O, McGuire M. Real-world patterns of care for patients with follicular lymphoma treated with lenalidomide and rituximab (R2) in the US Medicare population. *American Society of Hematology (ASH) Annual Meeting*. Atlanta, GA: December 9-12, 2017.
177. Xie L, Zhou FL, Pan C, Vaidya N, Ye F, Preblich R, Meneghini L. Impact of treatment persistence on glycated haemoglobin A1c (HbA1c) trends among patients with type 2 diabetes newly initiated on basal insulin. *53rd European Association for the Study of Diabetes Annual Meeting*. Lisbon, Portugal: September 11-15, 2017.
178. Lopes RD, Di Fusco M, Keshishian A, Luo X, Li X, Masseria C, Hamilton M, Friend K, Gupta K, Mardekian J, Pan X, Baser O, Jones WS. Effectiveness and safety of apixaban versus other oral anticoagulants in older adults with non-valvular atrial fibrillation and concomitant coronary artery disease or peripheral arterial disease. *American Heart Association (AHA) Scientific Sessions 2017*. Anaheim, CA: November 11-15, 2017.
179. Deitelzweig S, Keshishian A, Li X, Hamilton M, Masseria C, Gupta K, Luo X, Mardekian J, Friend K, Nadkarni A, Pan X, Lip GYH. Effectiveness and safety of apixaban, dabigatran, and rivaroxaban among non-valvular atrial fibrillation patients: A propensity score matched analysis of four large databases. *American Heart Association (AHA) Scientific Sessions 2017*. Anaheim, CA: November 11-15, 2017.
180. Amin A, Keshishian A, Trocio J, Dina O, Le H, Rosenblatt L, Liu X, Mardekian J, Zhang Q, Baser O, Vo L. Risk of stroke and major bleeding for dabigatran, rivaroxaban, and warfarin compared to apixaban among non-valvular atrial fibrillation patients in the United States Medicare population. *American Heart Association (AHA) Scientific Sessions 2017*. Anaheim, CA: November 11-15, 2017.
181. Gupta K, Mardekian J, Shank T, Keshishian A, Zhang Q, Trocio J. Comparisons of all-cause, stroke- and major bleeding-related medical costs among non-valvular atrial fibrillation patients who initiated oral anticoagulation therapies in the US Department of Defense Military Health System. *American Heart Association (AHA) Scientific Sessions 2017*. Anaheim, CA: November 11-15, 2017.
182. Lip GYH, Keshishian A, Li X, Hamilton M, Masseria C, Gupta K, Luo X, Mardekian J, Friend K, Nadkarni A, Pan X, Deitelzweig S. Effectiveness and safety of apixaban compared to other anticoagulants among non-valvular atrial fibrillation patients with coronary artery disease or peripheral arterial disease: A propensity score matched analysis of four large databases. *American Heart Association (AHA) Scientific Sessions 2017*. Anaheim, CA: November 11-15, 2017.
183. Xie L, Zhou L, Kariburyo F, Ye F, Meneghini L. Clinical outcomes of patients with type 2 diabetes who switched to insulin glargine 300 U/ml from insulin glargine 100 U/ml in real world US treatment settings. *Association of British Clinical Diabetologists (ABCD) Autumn Meeting*. London, United Kingdom: November 10, 2017.

184. Vaidya N, Wang Y, Xie L, Baser O. Evaluating the economic burden and health care utilization of bacterial pneumonia in the US Department of Defense population. *ISPOR 20th Annual European Congress*. Glasgow, Scotland: November 4-8, 2017.
185. Zhang Q, Kariburyo MF, Xu J, Xie L, Baser O. Examining health care utilization and costs among atherosclerosis patients in the US Veteran Health Administration population. *ISPOR 20th Annual European Congress*. Glasgow, Scotland: November 4-8, 2017.
186. Ogbomo A, Lin Y, Keshishian A, Xie L, Baser O. A comparative analysis of the health care utilization and costs of patients diagnosed with and without liver cancer in the US Medicare population. *ISPOR 20th Annual European Congress*. Glasgow, Scotland: November 4-8, 2017.
187. Wang L, Lewis-Black C, Fritschel E, Baser E. Comparison of various meta-analysis techniques. *ISPOR 20th Annual European Congress*. Glasgow, Scotland: November 4-8, 2017.
188. Yazici Y, Simsek I, Xie L, Ogbomo A, Parenti D, Goyal K, Teeple A, Ellis L. A real-world analysis of treatment patterns in a Turkish rheumatology population with continuous infliximab therapy or switched to biosimilar infliximab. *American College of Rheumatology (ACR) 2017 Annual Meeting*. San Diego, CA: November 3-8, 2017.
189. Nazareth T, Kariburyo F, Kirkemo A, Xie L, Pavlova-Wolf A, Bertels-Peculis L, Vaidya N, Sim J. Focal segmental glomerulosclerosis: A claims analysis of clinical and economic outcomes. *American Society of Nephrology (ASN) Kidney Week 2017*. New Orleans, LA: October 31 - November 5, 2017.
190. Nazareth T, Kariburyo F, Kirkemo A, Xie L, Pavlova-Wolf A, Bertels-Peculis L, Vaidya N, Sim J. Membranous nephropathy: A real-world clinical and economic analysis. *American Society of Nephrology (ASN) Kidney Week 2017*. New Orleans, LA: October 31 - November 5, 2017.
191. Ariely R, Chipps BE, Stoyanov S, Wang L, Shrestha S, Baser O. Budgetary impact model on a Medicare plan adopting short-acting beta-agonist inhalers with integrated dose counters. *2017 Annual Scientific Meeting of the American College of Allergy, Asthma & Immunology*. Boston, MA: October 26-30, 2017.
192. Kerwin EM, Stoyanov S, Wang L, Shrestha S, Baser O, Ariely R. The budget impact on the adoption of short-acting beta-agonist inhalers with integrated dose counters in managed care. *Academy of Managed Care Pharmacy (AMCP) Nexus 2017*. Dallas, TX: October 16-19, 2017.
193. Zhou FL, Xie L, Wang Y, Vaidya N, Meneghini LF. Lower hypoglycemia risk and better persistence in adults with type 2 diabetes after switch to insulin glargine 300 U/mL vs other basal insulins in real-world clinical settings. *Academy of Managed Care Pharmacy (AMCP) Nexus 2017*. Dallas, TX: October 16-19, 2017.
194. Hall E II, Wells W, Teynor M, Babb J, Huang A, Wang L, Baser O. Healthcare resource utilization and costs of spinal muscular atrophy care in the US Medicaid population. *Academy of Managed Care Pharmacy (AMCP) Nexus 2017*. Dallas, TX: October 16-19, 2017.
195. Mutlu E, Ogbomo A, Goyal K, Ellis L. Real-world utilization of biosimilar and originator infliximab in a cohort of patients with inflammatory bowel disease in Turkey. *Academy of Managed Care Pharmacy (AMCP) Nexus 2017*. Dallas, TX: October 16-19, 2017.
196. Shah A, Xie L, Kariburyo F, Zhang Q, Gore M. Real-world comparison of treatment patterns, health care resource utilization and costs in schizophrenia patients treated with long-acting injectable vs oral. *Academy of Managed Care Pharmacy (AMCP) Nexus 2017*. Dallas, TX: October 16-19, 2017.

197. Ellis L, Simsek I, Xie L, Ogbomo A, Goyal K, Yazici Y. Analysis of real-world treatment patterns in a matched sample of rheumatology patients with continuous infliximab therapy or switched to biosimilar infliximab. *Academy of Managed Care Pharmacy (AMCP) Nexus 2017*. Dallas, TX: October 16-19, 2017.
198. Huang A, Amos T, Joshi K, Wang L, Nash A. Burden of schizophrenia in recently diagnosed adult patients: A commercial payer perspective. *US Psych Congress 2017*. New Orleans, LA: September 16-19, 2017.
199. Benson C, Huang A, Wang L, Tandon N, Nash AI, Baser O. Clinical and economic burden of major depressive disorder among US veterans. *US Psych Congress 2017*. New Orleans, LA: September 16-19, 2017.
200. Shah A, Xie L, Kariburyo F, Zhang Q, Gore M. Treatment patterns, healthcare resource utilization and costs in schizophrenia patients treated with long-acting injectable vs oral antipsychotics: A real-world study. *US Psych Congress 2017*. New Orleans, LA: September 16-19, 2017.
201. Duncan M, Wang Y, Xie L, Baser O, Gore M. Prevalence and treatment patterns of opioid use disorder in two commercial populations. *US Psych Congress 2017*. New Orleans, LA: September 16-19, 2017.
202. Zhao Q, Wang L, Kurlansky PA, Schein J, Baser O, Berger JS. Impact of coronary artery disease on clinical outcomes among patients with newly-diagnosed heart failure with systolic dysfunction: Is it changing over time? *Heart Failure Society of America (HFSA) 21st Annual Scientific Meeting*. Dallas, TX: September 16-19, 2017.
203. Zhang Q, Xie L, Baser O, McGuire M. Evaluating treatment patterns of relapsed acute myeloid leukemia among the elderly in the United States. *Society of Hematologic Oncology (SOHO) Annual Meeting*. Houston, TX: September 13-16, 2017.
204. Taylor K, Araujo AB, Wang L, Boystov N, Haynes GB, Pandya S, Sietsema, Faries D, Baser O, Jones CB. Effectiveness of a private, orthopedic practice-based osteoporosis management program for prevention of recurrent fractures. *American Society for Bone and Mineral Research (ASBMR) 2017 Annual Meeting*. Denver, CO: September 8-11, 2017.
205. Vaidya N, Xie L, Wang Y, Du J, Baser O. Evaluating the economic burden and health care utilization of migraine in the US Department of Defense population. *International Society for Pharmacoepidemiology (ISPE) 33rd International Conference on Pharmacoepidemiology*. Montreal, Canada: August 26-30, 2017.
206. Ogbomo A, Keshishian A, Xie L, Lin Y, Baser O. A descriptive analysis of the health care utilization and costs of patients diagnosed with multiple myeloma in the US Medicare population. *International Society for Pharmacoepidemiology (ISPE) 33rd International Conference on Pharmacoepidemiology*. Montreal, Canada: August 26-30, 2017.
207. Zhao Q, Wang L, Kurlansky PA, Schein J, Baser O, Berger J. Short and intermediate term all-cause mortality among newly-diagnosed heart failure patients in the US Medicare population. *European Society of Cardiology (ESC) Congress 2017*. Barcelona, Spain: August 26-30, 2017.
208. Peacock WF, Coleman C, Wells P, Fermann GJ, Wang L, Baser O, Schein J, Crivera C. Clinical and economic outcomes in low-risk pulmonary embolism patients treated with rivaroxaban vs standard of care. *European Society of Cardiology (ESC) Congress 2017*. Barcelona, Spain: August 26-30, 2017.
209. Amin A, Keshishian A, Trocio J, Dina O, Le H, Rosenblatt L, Mardekian J, Zhang Q, Baser O, Liu X, Vo L. Risk of major bleeding among non-valvular atrial fibrillation patients prescribed apixaban, dabigatran, rivaroxaban, or warfarin in the US Medicare population. *European Society of Cardiology (ESC) Congress 2017*. Barcelona, Spain: August 26-30, 2017.

210. Lip GYH, Keshishian A, Li X, Lee TC, Mardekian J, Posner N, Luo X. Predictors of warfarin discontinuation or switching among non-valvular atrial fibrillation patients. *European Society of Cardiology (ESC) Congress 2017*. Barcelona, Spain: August 26-30, 2017.
211. Li X, Deitelzweig S, Keshishian A, Hamilton M, Horblyuk R, Gupta K, Luo X, Mardekian J, Friend K, Nadkarni A, Pan X, Lip GYH. Effectiveness and safety of apixaban versus warfarin among high-risk subgroups of non-valvular atrial fibrillation patients: a propensity score matched analysis. *European Society of Cardiology (ESC) Congress 2017*. Barcelona, Spain: August 26-30, 2017.
212. Li X, Lip GYH, Keshishian A, Hamilton M, Horblyuk R, Gupta K, Luo X, Mardekian J, Friend K, Nadkarni A, Pan X, Deitelzweig S. Effectiveness and safety of standard and lower dose apixaban compared to warfarin in non-valvular atrial fibrillation patients: a propensity score matched analysis. *European Society of Cardiology (ESC) Congress 2017*. Barcelona, Spain: August 26-30, 2017.
213. Pandya S, Cao Y, Wang L, Baser O. Assessing the economic burden and 30-day readmission rates among patients with heart failure in the US Veterans Health Administration population. *International Society for Pharmacoepidemiology (ISPE) 33rd International Conference on Pharmacoepidemiology*. Montreal, Canada: August 26-30, 2017.
214. Zhang Q, Xie L, Keshishian A, Lin Y, Baser O. Examining the health care utilization and costs among elderly patients with chronic obstructive pulmonary disease in the United States. *International Society for Pharmacoepidemiology (ISPE) 33rd International Conference on Pharmacoepidemiology*. Montreal, Canada: August 26-30, 2017.
215. Wells P, Peacock WF, Fermann GJ, Coleman CI, Wang L, Baser O, Schein J, Crivera C. The value of sPESI for risk stratification in patients with pulmonary embolism. *International Society on Thrombosis and Hemostasis (ISTH) 2017*. Berlin, Germany: July 8-13, 2017.
216. Phillips K, Juday T, Zhang Q, Keshishian A. Economic outcomes, treatment patterns, and adverse events and reactions for patients prescribed Infliximab or CT-P13 in the Turkish population. *European League Against Rheumatism (EULAR) Annual European Congress of Rheumatology*. Madrid, Spain: June 14-17, 2017.
217. Kuritzkes BA, Pappou EP, Guo X, Yang H, Zhao B, Baser O, Kiran RP, Bentley-Hibbert S. Visceral fat area, not body mass index, predicts postoperative 30-day morbidity in patients undergoing colon resection for cancer. *American Society of Colon and Rectal Surgeons (ASCRS) 2017 Annual Scientific and Tripartite Meeting*. Seattle, WA: June 10-14, 2017.
218. Zhou F, Xie L, Pan C, Vaidya N, Ye F, Preblich R, Meneghini L. Impact of treatment persistence on A1C trends among patients with T2D newly initiated on basal insulin. *American Diabetes Association (ADA) 77th Scientific Sessions*. San Diego, California: June 9-13, 2017.
219. Du J, Xie L, Keshishian A, Zhang Q, Yuce H, Baser O. Assessing the hospital readmission and mortality rates among elderly patients with chronic obstructive pulmonary disease. *ISPOR 22nd Annual International Meeting*. Boston, MA: May 20-24, 2017.
220. Xie L, Vaidya N, Wang Y, Tan H, Baser O. Evaluating the economic burden and health care utilization of prostate cancer patients in the US Department of Defense population. *ISPOR 22nd Annual International Meeting*. Boston, MA: May 20-24, 2017.
221. Vaidya N, Tan H, Xie L, Wang Y, Baser O. Evaluating the economic burden and health care utilization of rheumatoid arthritis patients in the US Department of Defense population. *International Society of Pharmacoeconomics and Outcomes Research (ISPOR) 22nd Annual International Meeting*. Boston, MA: May 20-24, 2017.

222. Borra S, Cao Y, Wang L, Baser O. Assessing the economic burden and 30-day readmission rates among patients with urinary tract infection in the US Veterans Health Administration population. *ISPOR 22nd Annual International Meeting*. Boston, MA: May 20-24, 2017.
223. Borra S, Cao Y, Wang L, Baser O. Assessing the economic burden and 30-day readmission rates among patients with pneumonia in the US Veterans Health Administration population. *ISPOR 22nd Annual International Meeting*. Boston, MA: May 20-24, 2017.
224. Borra S, Cao Y, Wang L, Baser O. Assessing the economic burden and 30-day readmission rates among patients with *clostridium difficile* infection in the US Veterans Health Administration population. *ISPOR 22nd Annual International Meeting*. Boston, MA: May 20-24, 2017.
225. Ogbomo A, Lin Y, Wang Y, Xie L, Yuce H, Baser O. A descriptive analysis of the health care utilization and costs of patients diagnosed with lymphoma in the US Medicare population. *ISPOR 22nd Annual International Meeting*. Boston, MA: May 20-24, 2017.
226. Lin Y, Ogbomo A, Wang Y, Xie L, Yuce H, Baser O. A descriptive analysis of the health care utilization and costs of patients diagnosed with myelodysplastic syndrome in the US Medicare population. *ISPOR 22nd Annual International Meeting*. Boston, MA: May 20-24, 2017.
227. Borra S, Cao Y, Wang L, Baser O. Assessing the economic burden and 30-day readmission rates among patients with urinary tract infection in the US Veterans Health Administration population. *International Society for Pharmacoeconomics and Outcomes Research (ISPOR) 22nd Annual International Meeting*. Boston MA: May 20-24, 2017.
228. Xie L, Zhang Q, Baser O, McGuire M. Examining the health care resource use and economic costs associated with acute myeloid leukemia among Medicare patients. *ISPOR 22nd Annual International Meeting*. Boston, MA: May 20-24, 2017.
229. Ganapathy V, Xie L, Keshishian A, Zhang Q, Baser O. Continuing care with nebulized bronchodilators after hospital discharge and impact on readmissions: Analysis of Medicare COPD beneficiaries receiving arformoterol vs nebulized short-acting agents. *American Thoracic Society (ATS) International Conference 2017*. Washington, DC: May 19-24, 2017.
230. Black CM, Fillit H, Xie L, Khandker RK, Kariburyo MF, Baser O, Yuce H, Ambegaonkar BM. Rates of institutionalization among newly-diagnosed Alzheimer's disease patients. *American Academy of Neurology (AAN) 69th Annual Meeting*. Boston, MA: April 22-28, 2017.
231. Black CM, Fillit H, Xie L, Khandker RK, Kariburyo MF, Baser O, Yuce H, Ambegaonkar BM. Cognition and activity impairment of newly diagnosed Alzheimer's disease patients in the Medicare Minimum Data Set. *American Academy of Neurology (AAN) 69th Annual Meeting*. Boston, MA: April 22-28, 2017.
232. Wang L, Baser O, Wells P, Peacock WF, Coleman CI, Fermann GJ, Schein J, Crivera C. Predictors of hospital length of stay among patients with low-risk pulmonary embolism. *Society of General Internal Medicine (SGIM) 2017 Annual Meeting*. Washington, DC: April 19-22, 2017.
233. Nazareth T, Kariburyo F, Pirani A, Kirkemo A, Xie L, Vaidya N, Philbin M. Patients with nephrotic syndrome (NS) receiving repository corticotrophin injection (RCI) or rituximab (RTX): Real-world (RW) evidence from a US claims analysis. *National Kidney Foundation (NKF) 2017 Spring Clinical Meetings*. Orlando, FL: April 18-22, 2017.
234. Black CM, Fillit H, Xie L, Khandker RK, Kariburyo MF, Baser O, Yuce H, Ambegaonkar BM. Cognition and activity impairment of newly diagnosed Alzheimer's disease patients in the Medicare Minimum Data Set. *13th International Conference on Alzheimer's & Parkinson's Diseases*. Vienna, Austria: March 29 - April 2, 2017.

235. Black CM, Fillit H, Xie L, Khandker RK, Kariburyo MF, Baser O, Yuce H, Ambegaonkar BM. Rates of institutionalization among newly diagnosed Alzheimer's disease patients. *13th International Conference on Alzheimer's & Parkinson's Diseases*. Vienna, Austria: March 29 - April 2, 2017.
236. Xie L, Parikh K, Abouzaid S, Pandya S, Baser O, Patel MI. Real-world treatment outcomes and costs among newly-diagnosed multiple myeloma patients treated with bortezomib and dexamethasone in combination with cyclophosphamide or lenalidomide. *13th Hematology/Oncology Pharmacy Association (HOPA) Annual Conference*. Anaheim, CA: March 29 - April 1, 2017.
237. Chipps B, Ferro T, Wang L, Shrestha S, Baser O, Parikh R. Healthcare costs in asthma and/or chronic obstructive pulmonary disease patients using albuterol inhalation aerosol with and without an integrated dose counter. *Academy of Managed Care Pharmacy (AMCP) Annual Meeting 2017*. Denver, CO: March 27-30, 2017.
238. Ganapathy V, Xie L, Wang Y, Zhang Q, Baser O. Prescription fill patterns after reaching the Medicare Part D coverage gap among chronic obstructive pulmonary disease patients on maintenance bronchodilators. *Academy of Managed Care Pharmacy (AMCP) Annual Meeting 2017*. Denver, CO: March 27-30, 2017.
239. Lee S, Xie L, Wang Y, Baser O. Evaluating the impact of treatment persistence on the economic burden of moderate-to-severe psoriasis and/or psoriatic arthritis patients in the US Department of Defense population. *Academy of Managed Care Pharmacy (AMCP) Managed Care Specialty Pharmacy Annual Meeting 2017*. Denver, CO: March 27-30, 2017.
240. Ye F, Zhou FL, Xie L, Kariburyo F, Meneghini L. Clinical outcomes of patients with type 2 diabetes (T2D) who switched to insulin glargine 300 U/mL (Gla-300) from insulin glargine 100 U/mL (Gla-100) in real-world US treatment settings. *Academy of Managed Care Pharmacy (AMCP) Managed Care Specialty Pharmacy Annual Meeting 2017*. Denver, CO: March 27-30, 2017.
241. Pandya S, Abouzaid S, Xie L, Parikh K, Baser O, Patel MI. Real-world health care costs among newly-diagnosed multiple myeloma patients in the United States veteran population (FY 2011-2015). *National Comprehensive Cancer Network (NCCN) 22nd Annual Conference*. Orlando, FL: March 23-25, 2017.
242. Amin A, Keshishian A, Trocio J, Dina O, Le H, Zhang Q, Baser O, Vo L. Effectiveness and safety of apixaban, dabigatran, and rivaroxaban compared to warfarin among non-valvular atrial fibrillation patients in the US Medicare population. *American College of Cardiology (ACC) 66th Annual Scientific Session & Expo*. Washington, DC: March 17-19, 2017.
243. Amin A, Keshishian A, Vo L, Mardekian J, Patel C, Odell K, Trocio J. Real-world comparison of major bleeding and associated costs among oral anticoagulant-naïve non-valvular atrial fibrillation patients initiating apixaban, dabigatran, rivaroxaban, or warfarin in the US Medicare population. *American College of Cardiology (ACC) 66th Annual Scientific Session & Expo*. Washington, DC: March 17-19, 2017.
244. Ganapathy V, Xie L, Wang Y, Zhang Q, Baser O. Hospital readmissions among chronic obstructive pulmonary disease patients treated in skilled nursing facilities in the US. *AMDA (Society for Post-acute and Long-term Care Medicine) Annual Conference 2017*. Phoenix, AZ: March 16-19, 2017.
245. Lee S, Xie L, Wang Y, Baser O. Evaluating the economic burden and incidence of comorbidities among moderate-to-severe PsO and/or PsA patients in the US Department of Defense population. *American Academy of Dermatology (AAD) 2017 Annual Meeting*. Orlando, FL: March 3-7, 2017.
246. Shrestha S, Baser O, Zhou X, Kwong WJ. Inappropriate dosing of oral anticoagulants among patients with non-valvular atrial fibrillation. *American Heart Association (AHA) International Stroke Conference (ISC) 2017*. Houston, TX: February 22-24, 2017.

247. Sonpavde G, Huang A, Wang L, Baser O, Miao R. First-line chemotherapy (CT) versus anti-androgen therapy (AT) for patients (pts) with metastatic castration-resistant prostate cancer (mCRPC): Individual patient analysis of the Veterans Health Administration (VHA) dataset. *2017 Genitourinary Cancers Symposium*. Orlando, FL: February 16-18, 2017.
248. Ganapathy V, Xie L, Wang Y, Zhang Q, Baser O. Time to reach coverage gap and catastrophic coverage: A Medicare Part D claims analysis among beneficiaries with chronic obstructive pulmonary disease. *American Society of Health-System Pharmacists (ASHP) 2016 Midyear Clinical Meeting*. Las Vegas, NV: December 4-8, 2016.
249. Peacock F, Baser O, Kohn C, Crivera C, Wang L, Schein J, Coleman C, Kumar N, Ashton V. External validation of a clinical and claims-based approach for predicting 90-day post-pulmonary embolism outcomes among US veterans. *American Society of Hematology (ASH) 58th Annual Meeting & Exposition*. San Diego, CA: December 3-6, 2016.
250. Huntington S, Keshishian A, Xie L, Baser O, McGuire M. Evaluating the economic burden and health care utilization following first-line therapy for diffuse large B-cell lymphoma patients in the US Medicare population. *American Society of Hematology (ASH) 58th Annual Meeting & Exposition*. San Diego, CA: December 3-6, 2016.
251. Parikh K, Pandya S, Abouzaid S, Baser O, Xie L, Patel MI. Real world treatment outcomes and cost among newly-diagnosed multiple myeloma patients treated with bortezomib and dexamethasone in combination with cyclophosphamide or lenalidomide. *American Society of Hematology (ASH) 58th Annual Meeting & Exposition*. San Diego, CA: December 3-6, 2016.
252. Copher R, Wang L, Wang J, Cavazos J. Racial differences in the incidence and prevalence of epilepsy in United States veteran population. *American Epilepsy Society (AES) Annual Meeting*. Houston, TX: December 2-6, 2016.
253. Kurlansky P, Baser O, Nemeth S, Tingley J, Argenziano M, Smith C. East meets west in the assessment of cardiac risk: A multicenter comparative study of the influence of racial, ethnic and cultural risk factors on cardiac surgical risk model performance. *American Heart Association (AHA) Scientific Sessions 2016*. New Orleans, LA: November 12-16, 2016.
254. Wang L, Baser O, Wells P, Peacock WF, Coleman C, Fermann GJ, Schein J, Crivera C. Benefit of early discharge among patients with low-risk pulmonary embolism: Focus on net clinical impact. *American Heart Association (AHA) Scientific Sessions 2016*. New Orleans, LA: November 12-16, 2016.
255. Amin A, Keshishian A, Vo L, Mardekian J, Singhal S, Patel C, Odell K, Trocio J. Real-world comparisons of major bleeding risk for commercially insured non-valvular atrial fibrillation patients initiating apixaban, dabigatran, rivaroxaban, or warfarin. *American Heart Association (AHA) Scientific Sessions 2016*. New Orleans, LA: November 12-16, 2016.
256. Lip GYH, Keshishian A, Kamble S, Pan X, Mardekian J, Horblyuk R, Hamilton M. Real world comparisons of major bleeding risk stratified by CHA2DS2-VASc scores among non-valvular atrial fibrillation patients initiating apixaban or warfarin. *American Heart Association (AHA) Scientific Sessions 2016*. New Orleans, LA: November 12-16, 2016.
257. Wang L, Baser O, Wells P, Peacock WF, Coleman C, Fermann GJ, Schein J, Crivera C. Effectiveness of rivaroxaban among patients diagnosed with pulmonary embolism. *American Heart Association (AHA) Scientific Sessions 2016*. New Orleans, LA: November 12-16, 2016.
258. Yazici Y, Xie L, Ogbomo A, Parenti D, Goyal K, Teeple A, Ellis L, Simsek I. A descriptive analysis of real-world treatment patterns of innovator infliximab (Remicade) and biosimilar infliximab in a treatment naïve Turkish rheumatologic disease population. *American College of Rheumatology (ACR)/ARHP Annual Meeting*. Washington, DC: November 11-16, 2016.

259. Shrestha S, Miao R, Wang L, Chao J, Yuce H, Wei W. Burden of atopic dermatitis among adults in a state Medicaid program (Medi-Cal). *American College of Allergy, Asthma & Immunology (ACAAI) 2016 Annual Scientific Meeting*. San Francisco, CA: November 10-14, 2016.
260. Xie L, Vaidya N, Xin K, Kariburyo MF, Yuce H, Baser O. Evaluating the economic burden and health care utilization of breast cancer in the US Medicare population. *International Society of Pharmacoeconomics and Outcomes Research (ISPOR) 19th Annual European Congress*. Vienna, Austria: October 29 - November 2, 2016.
261. Wang L, Li L, Pandya S, Baser O. A real-world evaluation of the clinical and economic burden of United States veteran patients with post-traumatic stress disorder. *International Society of Pharmacoeconomics and Outcomes Research (ISPOR) 19th Annual European Congress*. Vienna, Austria: October 29 - November 2, 2016.
262. Xie L, Vaidya N, Xin K, Keshishian A, Yuce H, Özenbas D, Baser O. Evaluating the economic burden and health care utilization of lung cancer in the US Medicare population. *International Society of Pharmacoeconomics and Outcomes Research (ISPOR) 19th Annual European Congress*. Vienna, Austria: October 29 - November 2, 2016.
263. Xie L, Zhang Q, Xin K, Wang Y, Yuce H, Özenbas D, Baser O. Health care utilization and economic burden of pancreatic cancer in the US Medicare population. *International Society of Pharmacoeconomics and Outcomes Research (ISPOR) 19th Annual European Congress*. Vienna, Austria: October 29 - November 2, 2016.
264. Wang L, Li L, Zhou X, Pandya S, Baser O. Assessing the clinical and economic burden of prostate cancer in the United States veteran population. *International Society of Pharmacoeconomics and Outcomes Research (ISPOR) 19th Annual European Congress*. Vienna, Austria: October 29 - November 2, 2016.
265. Wang L, Li L, Zhou X, Pandya S, Baser O. Evaluation of the clinical characteristics and economic burden of United States veteran patients diagnosed with the hepatitis C virus. *International Society of Pharmacoeconomics and Outcomes Research (ISPOR) 19th Annual European Congress*. Vienna, Austria: October 29 - November 2, 2016.
266. Wang L, Li L, Pandya S, Baser O. Evaluating socio-demographic characteristics of patients in the United States Department of Defense population. *International Society of Pharmacoeconomics and Outcomes Research (ISPOR) Congress 2016*. Vienna, Austria: October 29 - November 2, 2016.
267. Wang L, Sung A, Marcella S, Mohamed O. Burden of *clostridium difficile* infection (CDI) across hospital inpatient, nursing home, and home settings. *Infectious Diseases Society of America (IDSA) Infectious Disease Week (IDWeek)*. New Orleans, LA: October 26-30, 2016.
268. Murray AC, Baser O, Pappou LK, Feingold RP, Kiran. Income, geography and hospital determine gaps in assimilation of minimally invasive technology for rectal cancer surgery. *American College of Surgeons Clinical Congress*. Washington, DC: October 16-20, 2016.
269. Yazici Y, Simsek I, Xie L, Ogbomo A, Parenti D, Goyal K, Teeple A, Ellis L. A descriptive analysis of real-world treatment patterns in a Turkish rheumatology population that continued innovator infliximab (Remicade) therapy or switched to biosimilar infliximab. *Academy of Managed Care Pharmacy (AMCP) Nexus*. National Harbor, MD: October 3-6, 2016.
270. Xie L, Zhou S, Kariburyo F, Baser O, Fan T. Clinical and economic outcomes in patients with type 2 diabetes switching from basal insulin plus rapid-acting insulin to basal insulin plus glucagon-like peptide-1: A real-world observational study. *Academy of Managed Care Pharmacy (AMCP) Nexus*. National Harbor, MD: October 3-6, 2016.

271. Amin A, Keshishian A, Vo L, Mardekian J, Patel C, Odell K, Trocio J. Real-world comparison of major bleeding and associated costs among treatment-naïve non-valvular atrial fibrillation patients initiating apixaban, dabigatran, rivaroxaban, or warfarin. *Academy of Managed Care Pharmacy (AMCP) Nexus*. National Harbor, MD: October 3-6, 2016.
272. Parasuraman S, Yu J, Paranagama D, Shrestha S, Wang L, Baser O. Demographic and clinical characteristics of patients with polycythemia vera (PV) in the US veterans population. *Association of VA Hematology/Oncology (AVAHO) 12th Annual Meeting*. Dallas, TX: September 23-25, 2016.
273. Parikh K, Pandya S, Abouzaid S, Baser O, Xie L, Patel MI. Treatment patterns among newly diagnosed multiple myeloma patients in the United States Veteran Population (2010-2015). *2016 ASH Meeting on Hematologic Malignancies*. Chicago, IL: September 16-17, 2016.
274. Kamble S, Keshishian A, Pan X, Mardekian J, Horbkyuk R, Hamilton M, Lip GYH. Real-world comparisons of major bleeding risk and associated hospitalization costs among elderly non-valvular atrial fibrillation patients newly initiated on apixaban or warfarin. *European Society of Cardiology (ESC) Congress 2016*. Rome, Italy: August 27-31, 2016.
275. Lip GYH, Keshishian A, Kamble S, Pan X, Burns L, Mardekian J, Horbkyuk R, Hamilton M. Is major bleeding risk for oral anticoagulants similar between non-valvular atrial fibrillation patients newly initiated on warfarin and propensity-score matched NOAC initiators? A real world study. *European Society of Cardiology (ESC) Congress 2016*. Rome, Italy: August 27-31, 2016.
276. Lip GYH, Keshishian A, Shital K, Pan X, Burns L, Mardekian J, Horbkyuk R, Hamilton M. Major bleeding risk in patients aged 75 years or older with non-valvular atrial fibrillation initiating oral anticoagulants: a real-world comparison of warfarin, apixaban, dabigatran, or rivaroxaban. *European Society of Cardiology (ESC) Congress 2016*. Rome, Italy: August 27-31, 2016.
277. Amin A, Keshishian A, Xie L, Baser O, Price K, Vo L, Mardekian J, Mendoza M, Singhal S, Patel C, Odell K, Trocio J. Real-world comparison of major bleeding and associated costs among treatment-naïve non-valvular atrial fibrillation patients initiating apixaban or warfarin. *European Society of Cardiology (ESC) Congress 2016*. Rome, Italy: August 27-31, 2016.
278. Cole A, Shrestha S, Baser E. Prevalence of Crigler-Najjar in the Turkish Population. *32nd International Conference for Pharmacoepidemiology (ICPE/ISPE)*. Dublin, Ireland: August 25-28, 2016.
279. Black CM, Hu X, Khandker RK, Ambegaonkar BM, Kariburyo MF, Xie L, Baser O, Yuce H. Comparison of all-cause mortality rate and economic burden between newly diagnosed Alzheimer's disease patients who received anti-dementia treatment versus not: A longitudinal retrospective study. *Alzheimer's Association International Conference (AAIC) Annual Conference*. Toronto, Canada: July 24-28, 2016.
280. Cai J, Wang Y, Baser O, Xie L, Diels J, Neslusan C, Chow W. Comparative persistence with antihyperglycemic agents (AHA) used to treat type 2 diabetes mellitus (T2DM) in the real world. *American Diabetes Association (ADA) 76th Scientific Sessions*. New Orleans, LA: June 10-14, 2016.
281. Wei W, Knapp K, Wang L, Chen CI, Craig G, Ferguson K, Schwartzman S. Real-world treatment persistence and clinical outcomes of TNFi cycling vs switching to new mechanism of action DMARDs among patients with rheumatoid arthritis in the United States. *2016 European League Against Rheumatism (EULAR) Annual Congress*. London, United Kingdom: June 8-11, 2016.
282. Bashyal R, Du H, Wang L, Baser O. Examining the incidence and prevalence of alcohol dependence among US veteran patients. *International Society for Pharmacoeconomics and Outcomes Research (ISPOR) 21st Annual International Meeting*. Washington, DC: May 21-25, 2016.

283. Kariburyo F, Du J, Xie L, Baser O. Examining the health care resource utilization and economic burden among rheumatoid arthritis patients with different routine assessment of patient index data 3 scores: A probabilistic matching study. *International Society for Pharmacoeconomics and Outcomes Research (ISPOR) 21st Annual International Meeting*. Washington, DC: May 21-25, 2016.
284. Zhang Q, Zhao Y, Keshishian A, Xie L, Yuce H, Baser O. Assessing the economic burden and health care utilization of attention deficit/hyperactivity disorder among US Medicaid patients. *International Society for Pharmacoeconomics and Outcomes Research (ISPOR) 21st Annual International Meeting*. Washington, DC: May 21-25, 2016.
285. Kariburyo F, Du J, Xie L, Baser O. Assessing the economic burden of rheumatoid arthritis patients with different clinical disease activity index scores: a probabilistic matching study. *International Society for Pharmacoeconomics and Outcomes Research (ISPOR) 21st Annual International Meeting*. Washington, DC: May 21-25, 2016.
286. Bashyal R, Du H, Wang L, Yuce H, Baser O. Mortality and prevalence of major depressive disorder in the US Medicare population from 2008-2013. *International Society for Pharmacoeconomics and Outcomes Research (ISPOR) 21st Annual International Meeting*. Washington, DC: May 21-25, 2016.
287. Keshishian A, Du J, Xie L, Yuce H, Baser O. Demographic and socioeconomic characteristics that impact selection of oral anticoagulants among non-valvular atrial fibrillation patients. *International Society for Pharmacoeconomics and Outcomes Research (ISPOR) 21st Annual International Meeting*. Washington, DC: May 21-25, 2016.
288. Pandya S, Du H, Wang L, Baser O. Examining the prevalence and incidence rates among patients with drug dependence in the US veteran population. *International Society for Pharmacoeconomics and Outcomes Research (ISPOR) 21st Annual International Meeting*. Washington, DC: May 21-25, 2016.
289. Pandya S, Du H, Wang L, Baser O. Examining the prevalence and incidence rates among patients with depressive disorder in the US veteran population. *International Society for Pharmacoeconomics and Outcomes Research (ISPOR) 21st Annual International Meeting*. Washington, DC: May 21-25, 2016.
290. Tan H, Xie L, Baser O, Yuce H, Wang Y. Evaluating the economic burden and health care utilization of anemia in the US Medicare population. *International Society for Pharmacoeconomics and Outcomes Research (ISPOR) 21st Annual International Meeting*. Washington, DC: May 21-25, 2016.
291. Bashyal R, Du H, Wang L, Baser O. Examining the incidence and prevalence of bipolar disorder among U.S. veteran patients from 2011 to 2015. *International Society for Pharmacoeconomics and Outcomes Research (ISPOR) 21st Annual International Meeting*. Washington, DC: May 21-25, 2016.
292. Teeple A, Kariburyo MF, Ingham M, Tan H, Xie L. Differences between patient and physician perspectives toward starting biologics: Stratification by minority patient response vs white/undetermined patient response. *International Society for Pharmacoeconomics and Outcomes Research (ISPOR) 21st Annual International Meeting*. Washington, DC: May 21-25, 2016.
293. Pandya S, Du H, Wang L, Yuce H, Baser O. Mortality and rehospitalization rates among hospitalized congestive heart failure patients in the US Medicare population. *International Society for Pharmacoeconomics and Outcomes Research (ISPOR) 21st Annual International Meeting*. Washington, DC: May 21-25, 2016.
294. Pesa JA, Wang L, Yuce H, Baser O. Proton pump inhibitor utilization among patients with hepatitis C virus. *International Society for Pharmacoeconomics and Outcomes Research (ISPOR) 21st Annual International Meeting*. Washington, DC: May 21-25, 2016.

295. Keshishian A, Tan H, Xie L, Baser O. Examination of the economic burden of dyslipidemia in the Veterans Health Administration population. *International Society for Pharmacoeconomics and Outcomes Research (ISPOR) 21st Annual International Meeting*. Washington, DC: May 21-25, 2016.
296. Sanon M, Xie L, Bent-Ennakhil N, Coste F, Wang Y, Kariburyo MF, Neumann P, Fillit H. Health care utilization and costs in treated and non-treated US patients newly diagnosed with Alzheimer's disease. *International Society for Pharmacoeconomics and Outcomes Research (ISPOR) 21st Annual International Meeting*. Washington, DC: May 21-25, 2016.
297. Ogbomo A, Zhao Y, Kariburyo MF, Xie L, Yuce H, Baser O. Retrospective analysis of the economic burden of patients diagnosed with congestive heart failure in the California Medicaid population. *International Society for Pharmacoeconomics and Outcomes Research (ISPOR) 21st Annual International Meeting*. Washington, DC: May 21-25, 2016.
298. Zhang Q, Zhao Y, Keshishian A, Xie L, Yuce H, Baser O. Comparing health care resource utilization and costs among obese patients in the US Medicaid population. *International Society for Pharmacoeconomics and Outcomes Research (ISPOR) 21st Annual International Meeting*. Washington, DC: May 21-25, 2016.
299. Zhang Q, Zhao Y, Keshishian A, Xie L, Yuce H, Baser O. Evaluating the economic burden and health care utilization of coronary artery disease in the US Medi-Cal population. *International Society for Pharmacoeconomics and Outcomes Research (ISPOR) 21st Annual International Meeting*. Washington, DC: May 21-25, 2016.
300. Zhang Q, Zhao Y, Keshishian A, Xie L, Yuce H, Baser O. Evaluating asthma-related expenses and health care resource utilization among children in the US Medicaid population. *International Society for Pharmacoeconomics and Outcomes Research (ISPOR) 21st Annual International Meeting*. Washington, DC: May 21-25, 2016.
301. Bashyal R, Du H, Wang L, Yuce H, Baser O. Examining the mortality and readmission rates of patients diagnosed with stroke in the US Medicare population. *International Society for Pharmacoeconomics and Outcomes Research (ISPOR) 21st Annual International Meeting*. Washington, DC: May 21-25, 2016.
302. Pandya S, Du H, Wang L, Yuce H, Baser O. Mortality and rehospitalization rates among patients with chronic obstructive pulmonary disease in the US Medicare population. *International Society for Pharmacoeconomics and Outcomes Research (ISPOR) 21st Annual International Meeting*. Washington, DC: May 21-25, 2016.
303. Ogbomo A, Tan H, Kariburyo F, Xie L, Baser O. Assessing health care resource utilization and costs among US veterans diagnosed with asthma. *International Society for Pharmacoeconomics and Outcomes Research (ISPOR) 21st Annual International Meeting*. Washington, DC: May 21-25, 2016.
304. Ogbomo A, Tan H, Kariburyo F, Xie L, Baser O. Assessing the economic burden and health care resource utilization of US veterans with chronic obstructive pulmonary disease. *International Society for Pharmacoeconomics and Outcomes Research (ISPOR) 21st Annual International Meeting*. Washington, DC: May 21-25, 2016.
305. Tan H, Xie L, Wang Y, Yuce H, Baser O. Examine the burden of illness of US Medicare patients diagnosed with cataract. *International Society for Pharmacoeconomics and Outcomes Research (ISPOR) 21st Annual International Meeting*. Washington, DC: May 21-25, 2016.
306. Cheng E, Wang L, Morgenstern D, Asner I, Ta J, Jan A, Xie L, Kariburyo F, Wang Y, Meadows E. Healthcare costs among men with clinically localized prostate cancer managed with observation strategies versus immediate treatment in an integrated health care system. *International Society for Pharmacoeconomics and Outcomes Research (ISPOR) 21st Annual International Meeting*. Washington, DC: May 21-25, 2016.

307. Agashivala N, Keshishian A, Xie L, Greenberg S. Health care resource utilization and costs among patients diagnosed with sporadic inclusion body myositis in the US Medicare population. *Academy of Managed Care Pharmacy (AMCP) Annual Meeting*. San Francisco, CA: April 19-22, 2016.
308. Pesa JA, Doshi D, Wang L, Baser O. Description of health care utilization and costs among young, recently diagnosed schizophrenia patients one year prior to treatment with paliperidone palmitate once monthly injectable. *Academy of Managed Care Pharmacy (AMCP) Annual Meeting*. San Francisco, CA: April 19-22, 2016.
309. Xie L, Ingham M, Kariburyo F, Tan H, Teeple A. The classification and regression tree approach to predicting patient-specific factors associated with discussing biologic treatment with a health care provider in Crohn's disease patients. *Academy of Managed Care Pharmacy (AMCP) Annual Meeting*. San Francisco, CA: April 19-22, 2016.
310. Xie L, Ingham M, Kariburyo F, Tan H, Teeple A. Differences between patient and physician perspectives toward starting biologics: Stratification by patients who had a discussion about biologics with their physician vs those who did not. *Academy of Managed Care Pharmacy (AMCP) Annual Meeting*. San Francisco, CA: April 19-22, 2016.
311. Amin A, Keshishian A, Xie L, Baser O, Price K, Vo L, Mardekian J, Mendoza M, Singhal S, Patel C, Odell K, Trocio J. Real-world comparison of major bleeding risk among untreated non-valvular atrial fibrillation patients and those initiating apixaban, dabigatran, rivaroxaban, or warfarin. *American College of Cardiology (ACC) 65th Annual Scientific Session & Expo*. San Diego, CA: April 2-4, 2016.
312. Lip GYH, Keshishian A, Kamble S, Pan X, Burns L, Mardekian J, Masseria C, Bruno A, Phatak H. Real world comparison of major bleeding risk among non-valvular atrial fibrillation patients newly initiated on apixaban, warfarin, dabigatran or rivaroxaban: a 1:1 Propensity-score matched analysis. *American College of Cardiology (ACC) 65th Annual Scientific Session & Expo*. San Diego, CA: April 2-4, 2016.
313. Quek RGW, Fox KM, Wang L, Li L, Gandra SR, Wong ND. Increased incidence of cardiovascular disease events among diabetes patients with complications. *American Heart Association (AHA) Epidemiology and Prevention (EPI) / Lifestyle and Cardiometabolic Health 2016 Scientific Sessions*. Phoenix, AZ: March 1-6, 2016.